The QualityStocks Daily Stock List
- Transocean Ltd. (RIG)
- All for One Media Corp. (AFOM)
- Naked Brand Group Limited (NAKD)
- Propanc Biopharma, Inc. (PPCB)
- Creative Medical Technology Holdings, Inc. (CELZ)
- Boston Therapeutics, Inc. (BTHE)
- Stealth Technologies, Inc. (STTH)
- Syros Pharmaceuticals (SYRS)
- Force Protection Video Equipment Corp (FPVD)
- NantKwest Inc. (NK)
- ECGI Holdings Inc (ECGI)
- Amesite Inc. (AMST)
- Genius Brands International, Inc. (GNUS)
- CEL-SCI Corp. (CVM)
Transocean Ltd. (RIG)
Dividend Opportunities, DSR News, Greenbackers, Insider Wealth Alert, Investor Spec Sheet, Investors Alley, MicroCap Gems, MyBestStockAlerts, NetworkNewsWire, OTC Markets Group, Penny Stock General, Penny Stock Prodigy, PennyStocks24, PoliticsAndMyPortfolio.com, PremiereStockAlerts, ProfitableTrading, Promotion Stock Secrets, Pumps and Dumps, QualityStocks, SeriousTraders, Shiznit Stocks, SmallCapNetwork, Stock Commander, StocksToBuyNow, StreetAuthority Financial, The Trading Report, Tip.us, TopPennyStockMovers, TopStockAnalysts, Trade of the Week, Wall Street Daily, Wall Street Mover, Wyatt Investment Research and YOLOTraderAlerts reported earlier on Transocean Ltd. (RIG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Together with its subsidiaries, Transocean Ltd. provides offshore contract drilling services for oil and gas wells globally. It specializes in technically demanding sectors of the international offshore drilling business with a specific emphasis on ultra-deepwater and harsh environment drilling services. The Company also mainly provides drilling rigs, related equipment, as well as work crews. Transocean has its corporate headquarters in Steinhausen, Switzerland.
Transocean serves integrated oil companies or their affiliates. The Company also serves government-controlled oil companies and independent oil companies.
The Company owns or has partial ownership interests in, and operates a fleet of 45 mobile offshore drilling units. These comprise 28 ultra-deepwater floaters, 14 harsh environment floaters and three midwater floaters. Furthermore, Transocean is constructing two ultra-deepwater drillships.
In May of 2018, Transocean acquired Songa Offshore SE. This acquisition added seven floaters, four of which were high specification harsh environment. In December of 2018, the Company acquired Ocean Rig UDW. This acquisition added 11 floaters, including four 7th gen UDW drillships. In October of 2019, Transocean successfully deployed the world's first hybrid energy storage system aboard a floating unit, the Transocean Spitsbergen.
This past February, Transocean issued a quarterly Fleet Status Report. This Report provides the present status of, and contract information for, its fleet of offshore drilling rigs. Since its last Fleet Status Report in October of 2019, Transocean added roughly $366 million in contract backlog, bringing total backlog to $10.2 billion. The new contracts are for its Leiv Eiriksson, which was awarded a two-well contract, plus three one-well options in Norway; and Discoverer Inspiration, which was awarded a three-well contract, plus three one-well options in the U.S. Gulf of Mexico.
New contracts are also for Deepwater Asgard, which was awarded an estimated 200-day contract, plus four 74-day options in the U.S. Gulf of Mexico; and Development Driller III, which was awarded a one-year contract in Trinidad. New contracts are also in place for its Dhirubhai Deepwater KG2, awarded a 180-day contract, plus three one-well options in Myanmar; and Leiv Eiriksson, awarded a one-well contract in Norway.
Furthermore, new contracts are for Deepwater Invictus – a customer exercised a one-year option in the U.S. Gulf of Mexico; Transocean Norge – a customer exercised two one-well options in Norway; Deepwater Nautilus – a customer exercised 180-day option in Malaysia; and Deepwater Asgard – a customer exercised a 74-day option in the U.S. Gulf of Mexico.
Transocean Ltd. (RIG), closed Wednesday’s trading session at $3.73, up 34.1727%, on 140,782,717 volume with 227,130 trades. The average volume for the last 3 months is 39,347,624 and the stock's 52-week low/high is $0.649999976/$5.23999977.
All For One Media Corp. (AFOM)
Beacon Equity Research, DSR News, InvestorSoup, Jet-Life Penny Stocks, Penny Stock Craze, Penny Stock Finder, Penny Stock Hub, Penny Stock Prodigy, Penny Stock Titans, Penny Stocks Finder, PHUB News, ProTrader, QualityStocks, Small Cap Firm, Stock Preacher, SuperStockTips, The FrontPageStocks and Winston Small Cap reported earlier on All For One Media Corp. (AFOM), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
All For One Media Corp. is a tween marketing company listed on the OTC Markets’ OTCQB. Named “Generation I” for "Internet," this generation's tweens represent the first demographic to have had only known life with the Internet and social media. Essentially, All For One Media is a marketing brand changing the mindset of tweens that bullying is unacceptable. All For One Media has its head office in Mount Kisco, New York.
The Company is working to make the transition from a development stage corporation creating and acquiring media assets to a content provider launching many initiatives marketed to its core tween demographic. Its goal is to capitalize on a broad variety of potential revenue streams.
All For One Media, through entertainment, is working to deliver a message that will resonate with kids to impact the epidemic of bullying and cyber-bullying. In addition, it is working to help individuals who have been affected by bullying to deal with it in a positive and constructive manner.
All For One Media has produced Drama Drama (f/k/a "Crazy For the Boys"). Drama Drama is a full length coming of age musical dramedy. It features Groovy Tuesday music and choreography. This film tells the story of five high school girls from five very different cliques who must work together to run their school’s anti-bullying organization. The film features original pop songs pertaining to peer pressure, unrequited love, and teen angst. The expectation is that Drama Drama will generate revenues from numerous sources.
The Company has completed production of Drama Drama. It has started to screen the movie for buyers. Moreover, it engaged William Morris/Endeavor Content (WME) as the exclusive sales agent for the film. WME represents artists across all media platforms, particularly movies, television, music, theatre, digital and publishing.
All for One Media is making plans to commence group activities for the launch of the band "Drama Drama" concurrent to the release of the movie. The release of a full-length film used to promote the launch of a pop group is an industry first. The Company has also started negotiations with a number of major record labels for distribution of the film soundtrack.
All For One Media Corp. (AFOM), closed Wednesday’s trading session at $0.0016, up 45.4545%, on 305,444,009 volume with 427,690 trades. The average volume for the last 3 months is 159,341,358 and the stock's 52-week low/high is $0.000000999/$0.0052.
Naked Brand Group Limited (NAKD)
Awesome Stock Tips, AwesomeStocks, BUYINS.NET, Buzz Stocks, equities Canada, Equities.com, InvestorPlace, Jason Bond, MarketBeat, MarketClub Analysis, Money Morning, OTCtipReporter, Penny Pick Finders, Penny Stock 101, Penny Stock General, Penny Stock Titans, PennyStockLocks, PennyStockProphet, Profitable Trader Authority, ProfitableTrading, Promotion Stock Secrets, QualityStocks, RedChip, Schaeffer's, Shiznit Stocks, SmallCapVoice, Stock Beast, Stock Commander, Stock News Now, StockHideout, StockMarketWatch, StockOnion, StockRockandRoll, StreetInsider, TopPennyStockMovers, TopStockAnalysts, TraderPower, TradersPro, Trading Concepts, Vantage Wire and Wall Street Mover reported previously on Naked Brand Group Limited (NAKD), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Naked Brand Group Limited designs, manufactures, and sells men's and women's underwear, intimate apparel, loungewear, and sleepwear products. Its products are available in 44 countries through 6,000 retail doors, a growing network of E-commerce sites, and 61 company-owned Bendon retail and outlet stores in Australia and New Zealand. A unique fashion and lifestyle brand, Naked Brand Group has its corporate office in Alexandria, Australia.
Distinguished designer and sleepwear pioneer and Chief Executive Officer, Carole Hochman leads Naked Brand Group Limited. She joined the Company in 2014. Naked Brand Group’s intention is to expand into more apparel and product categories that exemplify the mission of the brand. This includes activewear, swimwear, sportswear, and more.
Naked Brand Group and Bendon Limited, an international leader in intimate apparel and swimwear, announced in June of 2018 that they completed their business combination. With this Merger Agreement, Naked Brand Group and Bendon became wholly-owned subsidiaries of a newly created company, Bendon Group Holding Limited, which was renamed Naked Brand Group Limited (Holdco).
Naked Brand Group designs, manufactures, and markets a portfolio of 11 company-owned and licensed brands. These cater to a broad cross-section of consumers and market segments. The Company’s brands include Naked, Bendon, Bendon Man, Davenport, Fayreform, Hickory, Lovable, Pleasure State, Heidi Klum Intimates, Heidi Klum Man, and Heidi Klum Swim.
Naked Brand Group Limited announced in November of 2018 that it closed its previously announced acquisition of the shares of FOH Online Corp. (FOH), the exclusive licensee of the Frederick’s of Hollywood brand for worldwide e-commerce business. With the acquisition, Naked Brand Group will control FOH’s exclusive license with the brand owner, Authentic Brands Group, which runs through 2020. It may be extended at FOH’s option through 2070.
Previously, Naked Brand Group completed an agreement with CVS Health and launched the Heidi Klum Intimates Solutions line to more than 4,000 CVS locations throughout the U.S. The Company also launched a new Diffusion program nationwide with Costco Wholesale Australia and launched a retail and outlet store expansion strategy throughout Australia and New Zealand. Furthermore, it appointed veteran apparel executives to accelerate the fast growing e-commerce channel.
Naked Brand Group Limited (NAKD), closed Wednesday’s trading session at $1.38, up 252.3104%, on 2,292,525,688 volume with 2,210,000 trades. The average volume for the last 3 months is 150,731,582 and the stock's 52-week low/high is $0.066100001/$2.61999988.
Propanc Biopharma, Inc. (PPCB)
MarketBeat, PoliticsAndMyPortfolio, QualityStocks and Wall Street Mover reported beforehand on Propanc Biopharma, Inc. (PPCB), and we report on the Company as well, here at the QualityStocks Daily Newsletter.
Propanc Biopharma, Inc. is a clinical stage Biopharmaceutical Company that focuses on the development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian, and colorectal cancers. The Company has developed a formulation of anti-cancer compounds that exert manifold effects designed to control or prevent tumors from recurring and spreading throughout the body. Propanc Biopharma is headquartered in Melbourne, Australia.
Propanc is developing a long-term therapy based on a pancreatic proenzyme formulation to prevent tumour recurrence and metastasis. Its lead product is PRP. This is a novel, patented, formulation comprising two proenzymes mixed in a synergetic ratio.
PRP is a solution for once daily intravenous administration of a combination of two pancreatic proenzymes, trypsinogen and chymotrypsinogen, for the treatment of pancreatic cancer. PRP is an enhanced proenzyme formulation designed to enhance the anti-cancer effects of multiple enzymes acting synergistically.
Propanc Biopharma has received Orphan Drug Designation (ODD) from the Food and Drug Administration (FDA) for the use of PRP. The approved indication is one of the most lethal malignancies with a median survival of 6 months and a 5-year survival rate of less than 5 percent.
The FDA granted Orphan Drug Designation status to PRP for the treatment of pancreatic cancer. After extensive laboratory research and a limited amount of human testing, Propanc Biopharma has evidence that PRP reduces cancer cell growth via promotion of cell differentiation; enhances cell adhesion and may suppress metastasis progression; and has no serious side effects and improves patient survival.
Recently, Propanc Biopharma announced that a cooperation agreement was entered into between the University of Jaén and Propanc to begin the POP1 joint drug discovery program to be co-funded by both parties. This agreement coincides with the appointment of research scientist, Mr. Aitor González, to lead the drug discovery and research activities over the next 3 to 4 years. The aim of this program is to identify and develop suitable backup compounds to Propanc’s lead product candidate, PRP. As part of the agreement, Macarena Perán, Ph.D. and Julian Kenyon, M.D. were appointed as joint supervisors, representing the University and Propanc Biopharma, respectively.
Propanc Biopharma, Inc. (PPCB), closed Wednesday’s trading session at $0.39, up 36.8901%, on 283,927 volume with 141 trades. The average volume for the last 3 months is 1,209,475 and the stock's 52-week low/high is $0.219999998/$230.00.
Creative Medical Technology Holdings, Inc. (CELZ)
Live Trading News, MarketWatch, Emerging Growth, Stockhouse, Bio Quick News, Capital Cube, OTC Markets, InvestorsHub, Canadian Insider, and 4-Traders reported earlier on reported earlier on Creative Medical Technology Holdings, Inc. (CELZ), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Creative Medical Technology Holdings, Inc. (CMT) is a clinical stage stem cell company listed on the OTC Markets Group’s OTCQB. The Company’s focus is on Urology and Neurology using stem cell treatments. Since 2011, CMT and its affiliate company, Creative Medical Health, Inc., have concentrated on regenerative medical solutions for unmet Urological and Neurological needs. The Company has a patent portfolio that encompasses all treatments. CMT has its corporate office in Phoenix, Arizona.
The Company has formed CaverStem International LLC. This is a majority-owned subsidiary centered on commercializing stem cell therapy for erectile dysfunction to global physicians and their patients. CaverStem is offering the Caverstem™ technology to selected physicians in the United States that qualify according to CMT's criteria.
CMT has also established CerebroStem LLC. This majority-owned subsidiary focuses on developing stem cell therapies for brain injuries and neurodegenerative diseases. Its initial focus will be treating radiation induced brain damage.
Via its own research and collaborations with top academic institutions, CMT has acquired a pioneering stem cell (AmnioStem) and developed proprietary protocols. Moreover, the Company has built an extensive intellectual property (IP) portfolio, developed complete treatment offerings for erectile dysfunction (ED), and launched a 40-patient trial for ED at UCLA. CMT is also making advances for treating stroke using its newly acquired amniotic fluid-based stem cell.
AmnioStem is Amniotic fluid derived stem cell. The AmnioStem patent covers means to isolate, grow, and use amniotic fluid derived stem cells in a scalable and commercializable way. AmnioStem cells do not necessitate matching with the recipient, as one size fits all.
Recently, CMT announced an update of its activities. Regarding CaverStem domestic activities, the Company is continuing marketing to physicians throughout the U.S. Additional physicians are scheduled for training, patients are being treated and revenues are being generated and growing each month. CMT anticipates reaching financial self-sufficiency by revenues from sales this year.
Creative Medical Technology Holdings, Inc. (CELZ), closed Wednesday’s trading session at $0.0325, up 41.3043%, on 94,458,127 volume with 2,314 trades. The average volume for the last 3 months is 135,744,742 and the stock's 52-week low/high is $0.0013/$0.07.
Boston Therapeutics, Inc. (BTHE)
FeedBlitz, Information Solutions Group, MarketBeat, MissionIR, PennyStocks24, QualityStocks, RedChip, SmallCapVoice, Stock News Now, TaglichBrothers, Tiny Gems, Tip.us, TopPennyStockMovers and Wall Street Mover reported earlier on Boston Therapeutics, Inc. (BTHE), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Boston Therapeutics, Inc. is a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases. The Company’s product pipeline centers on developing and commercializing therapeutic molecules that address diabetes and inflammatory diseases. OTCQB-listed, Boston Therapeutics is based in Lawrence, Massachusetts.
The Company’s product pipeline includes BTI-320. This is a non-systemic, non-toxic, chewable complex carbohydrate-based compound. The design of it is to lessen post-meal glucose elevation. BTI-320 is a proprietary polysaccharide.
BTI-320 works in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes, which break down complex carbohydrates into simple sugars, reducing the availability of glucose for absorption into the bloodstream.
Boston Therapeutics entered a clinical trial agreement with Joslin Diabetes Center to be the lead clinic in a Phase II study of BTI-320. In addition, the Company’s product pipeline includes IPOXYN™. This is an injectable anti-necrosis drug. The design of it at first is to treat lower limb ischemia associated with diabetes.
Boston Therapeutics’ product pipeline also includes OXYFEX™. This product can serve as the only available oxygen delivery mechanism for animals suffering ischemia or traumatic and surgical blood loss events. OXYFEX™ is the Company’s veterinary facsimile to IPOXYN™.
Furthermore, Boston Therapeutics developed and markets SUGARDOWN®. This is a non-systemic, complex carbohydrate-based dietary food supplement. The design of SUGARDOWN® is to support healthy blood glucose.
SUGARDOWN®, in its present formulation, is a natural sugar blocker dietary supplement product made completely from a non-digestible sugar molecule, which can help people maintain healthier weight levels. It is the first chewable tablet of its kind.
In 2015, Boston Therapeutics announced that its affiliate, Advance Pharmaceutical Company Limited (APC), began the SUGARDOWN® clinical trial in Hong Kong. Advance is evaluating the effect of SUGARDOWN® on Post-Prandial Hyperglycemia in Chinese subjects with Pre-Diabetes. The lead clinical site is the Department of Medicine, The Chinese University of Hong Kong (CUHK), Prince of Wales Hospital.
Boston Therapeutics and Advance Pharmaceutical previously announced the fully funded new trial plans to support the safety and efficacy of BTI-320, starting with a randomized, placebo-controlled, double-blinded, multi-center, global study on type 2 diabetic (T2D) patients.
Recently, Boston Therapeutics announced that effective sugar reduction with the investigative BTI-320 formulation necessitates only one tablet. Findings were confirmed by the most recent proof-of-concept study conducted in high-risk Chinese subjects with pre-diabetes. A formulation, in the form of a dietary supplement, is currently available as SUGARDOWN®, SUGARBLOCK and SUGARBALANCE in the Unites States and Asia.
Moreover, Boston Therapeutics previously announced that it expanded its partnership with Advance Pharmaceutical Company Limited (APC) to distribute in Korea. Following the extension of the licensing and distribution agreement with APC, a registered formulation, marketed as a food supplement under the name SUGARBALANCE is now available in Korea. This significant shipment marks a start to the sales of SUGARBALANCE in the territory.
Boston Therapeutics, Inc. (BTHE), closed Wednesday’s trading session at $0.05, up 91.9386%, on 291,965 volume with 31 trades. The average volume for the last 3 months is 122,538 and the stock's 52-week low/high is $0.005499999/$0.067000001.
Stealth Technologies, Inc. (STTH)
Buzz Stocks, Epic Stock Picks, NetworkNewsWire, OTCtipReporter, Penny Pick Finders, PennyStockProphet, Planet Penny Stocks, Profitable Trader Authority, QualityStocks, RedChip, SeriousTraders, StockOnion, StocksToBuyNow, Tip.us and Wolf of Penny Stocks reported previously on Stealth Technologies, Inc. (STTH), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Stealth Technologies, Inc. is a technology business listed on the OTC Markets Group’s OTCQB. The Company previously went by the name Excelsis Investments, Inc. It changed its name to Stealth Technologies, Inc. in July 2016. Stealth Technologies engages in identifying and capitalizing on technology and associated markets. The Company produces products for personal and financial protection.
Incorporated in 2010, Stealth Technologies has its corporate office in Largo, Florida. It became public through a reverse merger in 2012.
Moreover, Stealth Technologies announced in March of this year the completion of five new products. Currently, these products are staged in a large direct response retailer's quality assurance and legal department. They are under final review to ensure that marketing claims associated with each product are accurate when measured against actual performance levels of each product, and that assurance and inventory is satisfactory and has met all quality control factors. Stealth Technologies’ strategic initiative is to expand its product footprint across varied industries and distributors.
The Company has developed a group of products to protect against "electronic pickpockets," emergency response latency, credit fraud protection, and cell phone data protection. Its initial product to market is the Stealth Card.
The design of the Stealth Card is to protect the Radio-Frequency Identification (RFID) chip in a consumer's credit card from electronic stealing or pickpocketing, which uses a smartphone, credit card reader, or RFID antenna to remotely access data stored on the consumer's Smartchip. Stealth Card renders the chipped information invisible to intrusion.
The Stealth Card is a 100 percent USA product. The Stealth Card is manufactured from Stealth Technologies’ laboratory and research/development facility in West Virginia to its manufacturing facility in Massachusetts.
Development for the Stealth Card started in 2012. This is when Company Founder and Chief Executive Officer (CEO), President, and Director, Mr. Brian McFadden, observed the worldwide shift towards smart chip card technology to transmit and process credit card/debit card transactions. With Europe and Asia already making the transition away from the magnetic strip to smart chip cards, Mr. McFadden believed the United States market would need to follow suit.
To use the Stealth Card, a person places a Stealth Card in their wallet, pocket, change purse or anywhere they carry their credit cards. One card can protect up to 12 cards in a wallet. The card can be physically placed anywhere in a wallet or pocket.
The card does not need to be in the front or back of one’s wallet. The Stealth Card provides effective protection irrespective of where it’s placed in relation to one’s credit cards.
Stealth Technologies previously announced the development of the 911 Help Now Generation II Product. The 911 Help Now product provides a direct two-way voice connection to emergency service providers. The 911 Help Now pendent works by pressing the Help Now button and then a person is connected.
Stealth Technologies has a number of other products under development. The Company is exploring potential military applications of its proprietary technologies.
Along with the Stealth Card and the 911 Help Now Generation II Product, Stealth Technologies’ portfolio includes Data Secure Plus, which is new to market. Its portfolio also includes Stealth Mobile.
Stealth Technologies, Inc. (STTH), closed Wednesday’s trading session at $0.036, up 38.4615%, on 375,603 volume with 30 trades. The average volume for the last 3 months is 415,671 and the stock's 52-week low/high is $0.0065/$0.090000003.
Syros Pharmaceuticals Inc. (SYRS)
Barchart, BUYINS.NET, Daily Trade Alert, InvestorPlace, MarketBeat, MarketClub Analysis, Schaeffer's, StockMarketWatch, StreetAuthority Daily, StreetInsider, Streetwise Reports, TradersPro and Wealth Insider Alert reported beforehand on Syros Pharmaceuticals Inc. (SYRS), and today we report on the Company, here at the QualityStocks Daily Newsletter.
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, announced that it has closed its underwritten public offering.
The offering was comprised of 5,400,000 shares of common stock that were sold at $14 per share. In the announcement, the company noted that the public offering resulted in the gross proceeds of approximately $75.6 million, which Syros anticipates it will use to fund the development of its ongoing clinical and preclinical programs; the company may also use the monies for working capital and other general corporate purposes.
Along with the closing, Syros noted that it had granted the underwriters a 30-day option to purchase an additional 810,000 shares of common stock. Co-manager for the offering was Roth Capital Partners.
For more information, visit the company’s website at www.Syros.com.
About Syros Pharmaceuticals
Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches.
Syros is advancing a robust clinical-stage pipeline, including SY-1425, a first-in-class oral selective RAR¿ agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors.
Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.
Syros Pharmaceuticals Inc. (SYRS), closed Wednesday’s trading session at $10.44, off by 7.8553%, on 798,722 volume. The average volume for the last 3 months is 729,567 and the stock's 52-week low/high is $4.26000022/$15.6499004.
Force Protection Video Equipment Corp. (FPVD)
AimHighProfits, Insider Financial, Promotion Stock Secrets and QualityStocks reported previously on Force Protection Video Equipment Corp. (FPVD), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
A recent Pew Research article pinpointed major concerns with social media platforms. “Americans have complicated feelings about their relationship with big technology companies,” the article observes. “While they have appreciated the impact of technology over recent decades and rely on these companies’ products to communicate, shop and get news, many have also grown critical of the industry.” The article goes on to report that a Pew Research Center survey found that “roughly three-quarters of U.S. adults say it is very (37%) or somewhat (36%) likely that social media sites intentionally censor political viewpoints that they find objectionable.
Just 25% believe this is not likely the case.” The events of the last few weeks have made that article appear almost prophetic as issues of censorship and privacy have gained additional prominence on the world stage. A number of private and public companies are working to resolve these issues, with many of those companies relying on blockchain to provide their services.
Leading the pack is BIGtoken, the first consumer-managed data marketplace where people can own and earn from their data. The opportunity ahead has such potential that parent company SRAX Inc. (NASDAQ: SRAX) is spinning out BIGtoken into a separate publicly traded company and has entered into a definitive share exchange agreement with Force Protection Video Equipment Corp. (OTC: FPVD). The separation of BIGtoken provides shareholders a pure play in the consumer-managed data sector. SRAX benefits from the potential upside of the BIGtoken platform while reducing operating costs. Social media behemoths such as Facebook Inc. (NASDAQ: FB) and Twitter Inc. (NYSE: TWTR) are under pressure to identify and remove hate-filled communication along with taking added measures to protect consumer data. Blockchain companies such as Riot Blockchain Inc. (NASDAQ: RIOT) could benefit from increased implementation of blockchain technology to protect consumers, safeguard information and ensure data privacy. Everyone’s at risk as revealed by the recent Solarwinds hack, which compromised not just local, state and federal agencies but also major tech companies as well.
- Consumers starting to more deeply question growing censorship issues, lack of data control.
- Using blockchain, BIGtoken is first consumer-managed data marketplace where users can own, earn from their data.
- BIGtoken CEO writes that Privacy is fundamental human right whose time has come, and BIGtoken is pioneering the way forward.
Growing Concerns Surrounding Censorship, Privacy
Large social media sites now wield enormous power as they have become the dominant platforms of opinion and information. As they grew, they have used their codes of conduct to restrict certain opinions which is causing consumers to be acutely aware of the value of their personal data and driving them to alternative networks.
The issue of censorship on social media sites has never been more compelling — or divisive. A Jan. 14, 2021, Harvard Business Review article reported that “after years of controversy over President Trump’s use of social media to share misleading content and inflame his millions of followers, social media giants Facebook and Twitter finally took a clear stand last week, banning Trump from their platforms — Facebook indefinitely, and Twitter permanently.
To continue reading the article, click here https://www.ibn.fm/CJqix
Force Protection Video Equipment Corp. (FPVD), closed Wednesday’s trading session at $0.013, off by 39.5349%, on 135,877,787 volume with 2,137 trades. The average volume for the last 3 months is 20,185,001 and the stock's 52-week low/high is $0.000000999/$0.027499999.
NantKwest Inc. (NK)
BUYINS.NET, Daily Market Beat, Daily Trade Alert, Investing Futures, Investopedia, InvestorPlace, InvestorsUnderground, MarketBeat, Marketbeat.com, MarketClub Analysis, Stock Market Watch, StockMarketWatch, Street Insider, StreetInsider, The Street, TradersPro, Trades Of The Day and Zacks reported earlier on NantKwest Inc. (NK), and today we report on the Company, here at the QualityStocks Daily Newsletter.
Shares of NantKwest Inc. (NASDAQ:NK) traded today at $20.39, eclipsing its 52-week high. So far today approximately 3.5 million shares have been exchanged, as compared to an average 30-day volume of 3.5 million shares.
NantKwest Inc is a United States-based firm functioning in the healthcare sector. It is focused on providing immunotherapeutic agents, especially natural killer cells to treat cancer, infectious and inflammatory diseases. Natural Killer (NK) cells are ancient cells in the human body designed to recognize and detect cells under stress or infected.
The company's drug candidates such as activated NK cells, high-affinity NKs and target activated NK's address virally-induced cancers, viral, fungal and bacterial infections as well as critical diseases such as Ebola. Its pipeline product includes taNK, haNK, and aNK. Most of NatWest's sales are concentrated in the United States region although it has a reasonable market in Europe and other Non-U.S. territories.
NantKwest Inc. (NASDAQ:NK) is currently priced 11.5% above its average consensus analyst price target of $17.96.
NantKwest Inc. share prices have moved between a 52-week high of $20.39 and a 52-week low of $2.52 and are now trading 706% above that low price at $20.30 per share.
NantKwest Inc. (NK), closed Wednesday’s trading session at $19.76, up 3.2393%, on 1,477,632 volume. The average volume for the last 3 months is 2,165,691 and the stock's 52-week low/high is $2.51999998/$20.7800006.
ECGI Holdings Inc. (ECGI)
PennyTrader, QualityStocks, SmallCapVoice, StockHotTips and TopPennyStockMovers reported earlier on ECGI Holdings Inc. (ECGI), and we report on the Company as well, here at the QualityStocks Daily Newsletter.
ECGI Holdings (OTC: ECGI) has closed on its previously announced definitive agreement to acquire a farming property in California that is zoned for cannabis cultivation, processing and manufacturing. In the announcement, the company noted that the closure is ECGI’s first steps toward the development of its special cannabis acquisition model. The farm is a 1.7 million-square-foot property located in North California, which ECGI intends to use to cultivate premium cannabis strains.
The company will also build facilities on the property as it follows a strategic business model targeting regulated cannabis processing and manufacturing. The property is zoned for numerous cannabis business operations when appropriate licensures and approvals have been obtained. The Northern California farm is only the first of several similar acquisitions the company is pursuing.
The company has announced plan to change its corporate identity to Elite Cannabis Group Inc. and operate out of new offices in the Los Angeles area while still retaining its Nevada corporate business registration. “We are seeing there are numerous cannabis and hemp-related properties and businesses seeking to partner with companies that can apply financing and managerial expertise,” said ECGI CEO William Chung in the press release.
“ECGI is particularly interested in applying our team’s considerable expertise in cannabis and hemp extraction and in the manufacturing of ultra-high-quality concentrates as these market segments rapidly expand. We are currently performing due diligence on several other real properties and other assets in these related areas to add to a portfolio of investments.”
To view the full press release, visit http://cnw.fm/GT18F
About ECGI Holdings, Inc.
ECGI Holdings, which plans to operate as Elite Cannabis Group, is reorganizing as an acquisition-oriented corporation with California-based targets of distressed cannabis assets, properties zoned for cannabis cultivation and processing, and cannabis companies operating in market sectors with national expansion possibilities. For more information about the company, please visit info@ECGIHoldings.com.
ECGI Holdings Inc. (ECGI), closed Wednesday’s trading session at $0.95, up 21.7949%, on 5,650 volume with 7 trades. The average volume for the last 3 months is 2,934 and the stock's 52-week low/high is $0.100000001/$0.949999988.
Amesite Inc. (AMST)
007 Stock Chat, AllPennyStocks, Ceocast News, Fast Money Alerts, FeedBlitz, Gorilla Stock Trades, Greenbackers, Investor Ideas, Investor Stock Alerts, Ironman Stock, Jet-Life Penny Stocks, MassiveStockProfits, Mina Mar Marketing Group, OTCPicks, Otcstockexchange, Penny Stock General, Pennybuster, PennyStocks24, PennyStockSpy, QualityStocks, Shiznit Stocks, Stock Roach, Stock Shock and Awe, Stock Twiter, StockHideout, Whisper from Wall Street and Winston Small Cap reported beforehand on Amesite Inc. (AMST), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Amesite (NASDAQ: AMST), an artificial intelligence (“AI”) software company providing online learning ecosystems for business, higher education, and K-12, this morning announced the receipt of two awards from the National Association for Business Resources (“NABR”).
The NABR awards named Amesite one of the country’s best places to work and a top leader in wellness. “I’m so proud of what our team has been able to accomplish during an historically challenging year,” Amesite founder and CEO Dr. Ann Marie Sastry stated in the news release.
“To have us be recognized as one of the best and brightest places to work and also as a leader in employee wellness is a great honor, especially as we continue to grow following our IPO last year.”
To view the full press release, visit https://ibn.fm/qR0bN
About Amesite Inc.
Amesite is a high-tech artificial intelligence software company offering a cloud-based platform and content creation services for business, university and K-12 learning and upskilling. Amesite-offered courses and programs are branded to its customers. For more information, visit the company’s website at https://amesite.com.
Amesite Inc. (AMST), closed Wednesday’s trading session at $4.16, off by 7.3497%, on 34,790 volume. The average volume for the last 3 months is 45,195 and the stock's 52-week low/high is $3.65000009/$6.57999992.
CEL-SCI Corp. (CVM)
Bull Warrior Stocks, BullRally, BUYINS.NET, Ceocast News, ChartPoppers, CoolPennyStocks, CRWEPicks, CRWEWallStreet, Daily Trade Alert, Eagle Financial Publications, FeedBlitz, Green Energy Stocks, Greenbackers, Hit and Run Candle Sticks, HotOTC, HyperGrowthStock, Investment U, Investors Daily Edge, MadPennyStocks, MarketBeat, MarketClub Analysis, Mega Stock Pick, MicrocapAlliance, Momentum Trades, Money Morning, MonsterStocksPicks, OnTheMar, OTC Journal, OTC Picks, OTCJournal, OTCReporter, OTCtipReporter, Penny Invest, Pennybuster, PennyInvest, PennyOmega, PennyStockScholar, PennyStockVille, PoliticsAndMyPortfolio, Promotion Stock Secrets, QualityStocks, Round Up the Bulls, Schaeffer's, Sling-Shot-Stocks, SmallCap Network, SmallCapNetwork, SmallCapVoice, SmarTrend Newsletters, Stock Analyzer, Stock Fortune Teller, Stock News Now, Stock Rich, Stock Rocket Report, Stock Source, Stock Stars, StockBlogs, StockEgg, StockHotTips, StockMarketWatch, StockRich, Street Insider, StreetInsider, Streetwise Reports, TaglichBrothers, The Street, Tiny Gems, Today's Financial News, TooNiceStocks, Top Secret Stocks, TopPennyStockMovers, TraderPower, TradersPro, Trades Of The Day and Wall Street Resources reported previously on CEL-SCI Corp. (CVM), and today we report on the Company, here at the QualityStocks Daily Newsletter.
CEL-SCI Corp. (NYSE American: CVM) recently presented at the LD 500 and believes boosting a patient’s immune system while it is still intact should provide the greatest possible impact on survival. Therefore, in its global pivotal Phase 3 study, CEL-SCI treated patients who are newly diagnosed with advanced primary squamous cell carcinoma (cancer) of the head and neck with Multikine (leukocyte interleukin, injection) first, before they received surgery, radiation and/or chemotherapy.
This approach is unique. Most other cancer immunotherapies are administered only after conventional therapies have been tried and/or failed. Multikine has received Orphan Drug Designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck.
Multikine is designed to help the immune system ‘see’ the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. For more information, visit the company’s website at cel-sci.com
About The LD 500
The LD 500 is the most ambitious project in LD Micro’s 14-year history of leading the micro-cap space as an independent resource. Investors will enjoy updates from hundreds of companies that represent a wide variety of industries. Featuring some of the most prominent companies in the micro-cap world, the LD 500 also incorporates interviews and keynotes with small-cap royalty.
To view InvestorBrandNetwork’s virtual coverage, which includes one-click access to market research tools on the presenting companies, visit: http://ibn.fm/TheLD500
CEL-SCI Corp. (CVM), closed Wednesday’s trading session at $25.00, up 72.5328%, on 14,728,497 volume. The average volume for the last 3 months is 569,258 and the stock's 52-week low/high is $6.3499999/$40.9099998.
Genius Brands International (GNUS)
AllPennyStocks, Barchart, Beacon Equity Research, BUYINS.NET, Corporate Profile Media, Financial News Media, Greenbackers, InvestorPlace, Kiplinger Today, Market Intelligence Center Alert, MarketBeat, MarketClub Analysis, MicroStockProfit, Penny Stocks Finder, PennyStockNewsletter.info, PennyStocks24, QualityStocks, RedChip, Schaeffer's, Stock Preacher, Stock Roach, StockMarketWatch, StockOrange, StocksEarning, StreetInsider, The Momentum Traders Network, Timothy Sykes, TopPennyStockMovers, TraderPower, TradersPro, Trades Of The Day and Trading Concepts reported previously on Genius Brands International (GNUS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Genius Brands International (NASDAQ: GNUS), a global brand management company that creates, licenses and broadcasts multimedia entertainment content for children, today announced that John Landis, legendary multi-award-winning director and producer of blockbuster hits such as Trading Places, Animal House, Blues Brothers, Three Amigos, Beverly Hills Cop 2, Coming to America, and the Honey I Shrunk The Kids TV series, will join Arnold Schwarzenegger and the production team behind Genius Brands’ new children’s animated series, Stan Lee’s Superhero Kindergarten.
According to the update, Landis will direct Schwarzenegger, who lends his voice to the starring role of the action-adventure comedy series co-created by Stan Lee as one of his final projects. He also serves as co-producer, along with China’s Alibaba Group (NYSE: BABA), Stan Lee’s POW! Entertainment, and Schwarzenegger’s Oak Productions.
“When one has a property of this magnitude, we will quickly pursue development of a live-action feature spin-off as we work to maximize the value of the brand,” Genius Brands CEO and Chairman Andy Heyward said in the news release. “Today’s announcement reflects a core element of our strategy for Genius Brands and Kartoon Channel!–recruiting the industry’s top proven and emerging talent to ensure that we are steadily building a content offering that is second to none.
We believe that this approach, in combination with our excellent distribution deals and licensing agreements, is a pathway for Genius Brands to drive strong revenue and create long-term shareholder value.”
To view the full press release, visit http://nnw.fm/Fgu50
The company also recently announced that it has come to an agreement with all of its existing senior secured convertible noteholders to have the noteholders pre-pay their Notes for an aggregate of $4 million, three months early and then have the noteholders convert all of their $13.75 million of debt to equity. “This is a win-win for all parties. The Company today is debt free and holding $55 million in cash,” Andy Heyward, Chairman and CEO of Genius Brands, stated in the news release.
“The Company is uniquely positioned to take steps to build Kartoon Channel! into the pre-eminent childrens’ broadcaster anywhere, and produce, acquire, and license, the most compelling, forward-thinking programming for children today. We are delighted that our existing senior secured debt holders had the confidence in the Company to pre-pay the $4,000,000 Note obligation and to then convert their entire debt into equity right away.”
To view that full press release, visit http://nnw.fm/pLM5v
Genius Brands International (GNUS), closed Wednesday’s trading session at $3.06, up 81.0651%, on 215,897,969 volume. The average volume for the last 3 months is 23,930,241 and the stock's 52-week low/high is $0.051600001/$11.7299995.
The QualityStocks Company Corner
- DarioHealth Corp. (NASDAQ: DRIO)
- Genprex Inc. (NASDAQ: GNPX)
- SRAX Inc. (NASDAQ: SRAX)
- Exro Technologies Inc. (CSE: XRO) (OTCQB: EXROF)
- Cybin Inc. (NEO: CYBN) (OTC: CLXPF)
- Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF)
- Canopy Rivers Inc. (TSX: RIV) (OTC: CNPOF)
- CNS Pharmaceuticals Inc. (NASDAQ: CNSP)
- Predictive Oncology (NASDAQ: POAI)
- Green Hygienics Holdings Inc. (OTCQB: GRYN)
- GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF)
- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF)
- Josemaria Resources Inc. (TSX: JOSE) (OTC: JOSMF)
- InsuraGuest Technologies Inc. (TSXV: ISGI) (OTCQB: ISGIF)
DarioHealth Corp. (NASDAQ: DRIO)
DarioHealth Corp. (NASDAQ: DRIO) was featured today in a publication from BioMedWire, examining how the novel coronavirus has affected many countries, infecting roughly 96.2 million people across the globe. Of the 96 million individuals, about 53 million have recovered from this disease while nearly 2 million individuals have, sadly, succumbed to the deadly infection. Researchers have been trying to figure out how long the immunity of an individual who recovered from the disease will last. A recent study by Rockefeller University researchers provides an answer to this, suggesting that individuals who recover from the coronavirus are protected against the deadly infection for about six months, and likely much longer. Also today, the company was featured in a BioMedNewsBreaks from BioMedWire, examining how DRIO announced that it has entered into a definitive agreement to acquire Upright Technologies Ltd., a digital musculoskeletal (“MSK”) company; the acquisition will be in the form of a stock transaction. The acquisition is designed to expand DarioHealth's multi-condition platform into the $213 billion musculoskeletal market and create one of the most comprehensive digital health platforms. The move also brings together complementary companies with industry-leading consumer engagement and clinical outcomes. To view the full press release, visit: https://ibn.fm/VtZff
New York and Israel-based DarioHealth Corp. (NASDAQ: DRIO) leads global digital therapeutics (DTx) with its popular, smartphone-centered personalized chronic illness management software-as-a-service (SaaS). The company’s strategic advantages include:
- AI-powered digital solutions that drive durable behavior change in chronic disease patients, and
- Personalized user experience at scale to make behavior change the path of least resistance.
Approximately $3 trillion in annual U.S. costs associated with chronic illnesses like diabetes, hypertension and obesity are largely preventable with behavioral therapies. Formerly limited to periodic office visits, these therapies can now scale to millions with tech-enabled, continual and remote health monitoring, as well as AI-driven digital and live coaching. This is all possible while still maintaining the personalization required for success in reducing illness and its related effects and costs.
Roughly 51,000 active, paying users manage their health with Dario’s platform that combines smartphone-connected vitals measurement, remote patient monitoring (RPM), lifestyle management tools, and AI-driven and human coaching to deliver improved clinical outcomes.
Among the most downloaded medical apps, the Dario platform is rated at 4.9 stars on the Apple App Store and features 11,000 reviews, along with a Net Promoter Score (a measurement of consumers’ willingness to recommend the product to others) that’s the highest in its field.
Clinical studies demonstrate Dario’s direct improvement on users’ health measures like H1AC scores (diabetes) and blood pressure (hypertension).
Patient engagement in therapies leads to health success. Dario’s platform centers on continual maximization of patient engagement through personalization, including ‘nudges’ and live, AI-generated responses to health measures provided by Dario’s smartphone-connected medical devices.
Proprietary data analysis provides valuable insights that not only improve health care providers’ medical capabilities but, through artificial intelligence, encourage patients to take evidence-based and highly personalized preventative measures that reduce risk, emergency room visits and preventable hospitalization.
Dario is now deploying its successful B2C platform in B2B2C, targeting employers and health plans with competitive advantages in cost, software and hardware.
The company estimates an annual addressable U.S. market of $72 billion, only 1% of which has been penetrated with digital therapeutics.
The strategic transition to B2B2C (from exclusively B2B) is intended to accelerate revenue growth by reducing Dario’s cost per acquisition per user and expanding margins.
Dario’s commitment to aggressive growth is also shown by its appointment of a new president, chief medical officer and head of sales for North America, all from a highflyer behavioral health company.
Key growth drivers planned include expansion of the company’s paying B2C subscriber base; lateral expansion into other chronic conditions that overlap with its core diabetes populations, such as hypertension, obesity and depression; and increased B2B2C penetration.
The company plans to leverage a massive opportunity for growth, with a global addressable market for digital therapeutics of roughly $108 billion. In the U.S. alone, that number is estimated at $72 billion, and only about 1% of that market has been penetrated.
Dario’s strategic transition to an SaaS membership business model increased gross profit by 87% in Q1 2020, as compared to the prior year. Membership revenue increased from 27.1% to 46.7% in the same period. The company is seeing improved operating efficiencies as it shifts focus to the B2B2C business model, and it expects average revenue per user per month (ARPU), which was $6 and $25 in 2019 and 2020, respectively, to reach $70.
Value to Consumers and Businesses
Dario continually evaluates and optimizes the value and return its platform delivers to consumers and businesses.
Consumers seeking to understand how their everyday behavior impacts their personal health and chronic conditions benefit from actionable feedback on how to improve health and better collaborate with health care providers.
Businesses looking to increase employee satisfaction, loyalty and productivity with fewer health-related absences take advantage of Dario’s services for employers.
Health care providers improve patient compliance using the platform’s interactive services that allow for greater monitoring, which improve engagement with patients at the right times and with the right treatments.
Health plans can leverage DarioHealth’s solutions to improve patient outcomes and lower costs.
The company recently presented the results of two new studies at the American Diabetes Association’s 80th Scientific Sessions, which showed sustained improvements in blood glucose levels and blood pressure among users of its digital therapeutic platform for chronic diseases. The results of these two studies demonstrate that the use of Dario’s therapeutic platform promotes behavioral modification, enhanced individual engagement and improved clinical outcomes.
Remote Patient Monitoring (RPM) Agreements
The Centers for Medicare & Medicaid Services recently approved RPM codes for Medicare patients, which enables physicians to bill for between-visit patient care.
This simplifies implementation of the company’s open and scalable AI-driven platform and further supports transition to the company’s high-margin, recurring SaaS model targeting B2B2C revenue channels.
Emergency COVID-19 FDA Guidelines Allow Self-Test Blood Glucose Meters
In an effort to preserve personal protective equipment (PPE) and reduce contact between health care providers and patients in hospital settings due to COVID-19, the U.S. Food and Drug Administration (FDA) has recognized that home-use blood glucose meters, including Dario’s smartphone-connected metering device, may be used by patients with diabetes who are hospitalized due to COVID-19 to check their own blood glucose levels and provide the readings to the health care personnel caring for them.
As a result, hospitals can now allow patients to self-test using their Dario blood glucose testing strips and smartphone-connected devices, or hospitals can issue patients Dario devices upon admission for COVID-19-related conditions.
Irregularities in blood glucose levels are suspected as a factor in the increased severity of potentially deadly COVID-19 complications. As such, a high priority is being placed on stabilization of patients’ blood glucose levels.
Awards and Recognition
DarioHealth’s Blood Glucose Monitoring System was voted as the ‘Best Glucometer for Data Management’ by Top Ten Reviews. Jeph Preece, senior editor at Top Ten Reviews, said, “The Dario app is the best data management system that I’ve seen. Compared to apps by popular brands, Dario’s system looks and feels like it’s years ahead of the curve.”
‘The Global Digital Health 100’, an annual award sponsored by the reputable Journal of Health, recognized DarioHealth as a leader among health technology companies demonstrating the greatest potential to change the way that health care is delivered.
DarioHealth Corp. (DRIO), closed Wednesday’s trading session at $21.92, off by 6.6837%, on 296,598 volume. The average volume for the last 3 months is 116,332 and the stock's 52-week low/high is $3.01999998/$24.8899993.
- New Study Discovers Patient's Immune System Continues Building Resistance After Recovering from COVID-19
- BioMedNewsBreaks - DarioHealth Corp. (NASDAQ: DRIO) Signs Agreements to Acquire Leading Digital Musculoskeletal Company, Raise $70 Million Through Private Placement
- DarioHealth Announces Hiring of Leading Digital Health Innovator as Senior Vice President of Employer Sales
Genprex Inc. (NASDAQ: GNPX)
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, this morning announced that the company’s president and CEO Rodney Varner will present at the Virtual Investor Conference Small and Microcap Showcase at 11 AM ET on February 4, 2021. Varner will be providing a virtual company overview, including a synopsis of its diabetes gene therapy and details on the recent progress made on GNPX’s upcoming clinical trials for the treatment of non-small cell lung cancer. Following the conference, a replay of GNPX’s presentation will be available on the company’s website for a limited time. A video will also be archived on www.VirtualInvestorConferences.com. To register for the event, visit https://ibn.fm/VSD9k. To view the full press release, visit https://ibn.fm/9Lkao
Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.
Research and Development
Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.
Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.
Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.
Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.
TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.
Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.
Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.
Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.
Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.
Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.
Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.
Genprex Inc. (NASDAQ: GNPX), closed Wednesday’s trading session at $4.26, off by 6.7834%, on 1,659,248 volume. The average volume for the last 3 months is 1,307,600 and the stock's 52-week low/high is $1.16999995/$7.0300002.
- BioMedNewsBreaks - Genprex Inc. (NASDAQ: GNPX) CEO to Present at Upcoming Virtual Investor Conference Small and Microcap Showcase
- BioMedNewsBreaks - Genprex Inc. (NASDAQ: GNPX) Slated to Present Trailblazing Gene Therapies at the MoneyShow Accredited Investors Virtual Expo
- BioMedNewsBreaks - Genprex Inc. (NASDAQ: GNPX) Passes Final Release Tests for Manufacturing Run of Proprietary Immunogene Therapy Treatment
SRAX Inc. (NASDAQ: SRAX)
SRAX Inc. (NASDAQ: SRAX) was featured today in a publication from NetworkNewsWire, examining how a recent Pew Research article pinpointed major concerns with social media platforms. “Americans have complicated feelings about their relationship with big technology companies,” the article observes. “While they have appreciated the impact of technology over recent decades and rely on these companies’ products to communicate, shop and get news, many have also grown critical of the industry.” The article goes on to report that a Pew Research Center survey found that “roughly three-quarters of U.S. adults say it is very (37%) or somewhat (36%) likely that social media sites intentionally censor political viewpoints that they find objectionable. Just 25% believe this is not likely the case.” Also today, the company was highlighted in a publication from InvestorWire, examining how BIGToken, Inc. this morning announced the closing of its share exchange transaction with Force Protection Video Equipment (OTC: FPVD) resulting in BIGToken now being a public company by way of a reverse merger. To view the full press release, visit http://ibn.fm/EnTJ2
SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.
Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.
SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.
- SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
- SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
- SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
- SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
- SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
- SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.
BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.
The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.
Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.
Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.
SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.
BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.
The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.
SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.
BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.
Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.
Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.
SRAX Inc. (NASDAQ: SRAX), closed Wednesday’s trading session at $3.13, off by 9.5376%, on 627,871 volume. The average volume for the last 3 months is 203,274 and the stock's 52-week low/high is $1.50999999/$4.05000019.
- Censorship and Data: The Stakes and Consequences Are Getting Serious
- InvestorNewsbreaks - SRAX Inc.'s (NASDAQ: SRAX) BIGToken Announces Closing of Share Exchange Agreement with Force Protection Video Equipment Corp. (FPVD)
- SRAX Inc. (NASDAQ: SRAX) to Host, Present at B.Riley Securities 2021 Vision Day via its Virtual Events Platform
Exro Technologies Inc. (CSE: XRO) (OTCQB: EXROF)
Exro Technologies (TSX.V: EXRO) (OTCQB: EXROF), a leading clean-technology company that has developed a new class of power electronics for electric motors and batteries, has announced that Terence Johnsson has joined its Board of Directors. An automotive executive with global experience, Johnsson is a retired vice president from Audi AG, General Motors and Volkswagen AG and has racked up more than three decades of professional sales experience at top levels of these large automotive manufacturers. To view the full press release, visit https://ibn.fm/qtjYz
Exro Technologies Inc. (CSE: XRO) (OTCQB: EXROF), a Canadian technology company, is an innovative pioneer in the energy sector. Exro has developed and commercialized an electric power module (EPM) that integrates into existing motor systems to make them smarter. Exro’s patented technology optimizes existing motor performance by automatically sensing and adapting operating parameters to an optimized state, creating measurable efficiency gains, reduced mechanical components and increased system availability.
Exro’s technology and efficiency optimization algorithms improve the performance and efficiency of electric motors by manipulating power delivery to individual coils, thereby enabling the ability to expand operating parameters. This novel approach is scalable and can be utilized in most variable torque applications.
The widespread applications of Exro’s technology apply to optimizing the performance of electric vehicles, locomotive traction applications, industrial motors, and other variable torque applications that benefit from smart energy conversion.
Exro’s proprietary, patented software controls electric motor coils through individual coil switching. This introduction of intelligence into energy conversion at the level of individual coils results in expanded speed/torque capability, improved machine efficiency, reliability, safety and maintenance across a wider operating range. Exro’s advanced control algorithms create smart, real-time optimized power management.
Exro currently holds 15 patents, with 8 patents pending and additional patents under development. The company continues to expand its IP portfolio to support its goal of becoming a globally recognized leader in leveraging advanced control algorithms to improve the performance, efficiency and longevity of electric motors and generators.
Electric motors are the single biggest consumer of electricity. They account for about two-thirds of industrial power consumption and about 45% of global power consumption, according to an analysis by the International Energy Agency. Exro’s technology seeks to give industries a new way to look at energy—from electric vehicles, to industrial equipment, to renewable applications like wind farms; we are improving the way energy is consumed.
The 6,500-square-foot Exro Innovation Center (EIC), scheduled to open spring of 2020 in Calgary, will transition the current Victoria lab into one Calgary based center. The company’s new laboratory space will expand its service capabilities to customers, provide larger test capabilities, and showcase how Exro’s technology can be applied to dramatically improve the performance of electrical motors.
The EIC will also host collaborative events to explore advances in energy consumption and electric motor innovations, with participants from across Canada and around the world.
- A strategic agreement with Finland’s Aurora Powertrains Oy, which in 2019 released an all-electric production snowmobile called the “eSled,” will see Exro’s technology added to the Aurora electric powertrain. The snowmobile sector’s economic footprint is estimated at $26 billion in the U.S., $8 billion in Canada, and $5 billion in Europe and Asia.
- An agreement with Potencia in Mexico serving the last mile vehicle segment will integrate Exro’s custom drive and EPM module into small passenger commercial vehicles (taxis) and fleet delivery trucks
- A licensing agreement with Motorino Electric, a leader in the Canadian electric transportation industry, will integrate Exro’s Electric Power Module technology into Motorino’s CTi electric bicycle.
Chief Executive Officer Sue Ozdemir is a proven leader in the innovation and manufacturing of electric motors. She has nine years of accomplishments at General Electric, acting as CCO and the CEO of GE’s Small Industrial Motors Division, overseeing the division’s North American and international markets — ultimately building the division into a $160 million enterprise.
Chief Commercial Officer Josh Sobil is leading the seamless adoption of Exro’s growing product portfolio focused on the mobility segment and opening doors in all segments including agriculture, heavy industry, energy, construction, among others.
Executive Chairman Mark Godsy is a serial technology entrepreneur who has been involved in many top tier ventures, including two of Canada’s most successful biotech companies.
Exro Technologies Inc. (CSE: XRO) (OTCQB: EXROF), closed Wednesday’s trading session at $3.04, off by 1.9355%, on 487,859 volume with 657 trades. The average volume for the last 3 months is 303,333 and the stock's 52-week low/high is $0.150000005/$3.93000006.
- MiningNewsBreaks - Exro Technologies Inc. (TSX.V: EXRO) (OTCQB: EXROF) Names Audi Retired VP Terence Johnsson to Board
- InvestorNewsBreaks - Exro Technologies Inc. (TSX.V: EXRO) (OTCQB: EXROF) Announces Validation of Intelligent Battery Technology for Second Life Applications
- InvestorNewsBreaks - Exro Technologies Inc. (TSX.V: EXRO) (OTCQB: EXROF) CEO Featured in TMX Group Video Interview Series
Cybin Inc. (NEO: CYBN) (OTC: CLXPF)
Cybin Inc. (NEO: CYBN) (OTC: CLXPF) was featured today in a publication from PsychedelicNewsWire, examining how Justin Andrews, co-founder of Halifax Psychedelic Society, a not-for-profit organization providing a safe space to connect and talk about psychedelics, is concerned that information on harm minimization strategies with regard to psychedelics is not being treated as a priority in Nova Scotia. Andrews assisted in the establishment of the organization in 2018. The objective of the organization was to offer harm-reduction information and a support system to individuals who would be interested in using psychedelic substances such as LSD and psilocybin as a therapeutic treatment.
The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.
In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.
Serenity Life Sciences & Natures Journey Inc.
The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.
Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.
Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.
Partnership with the Toronto Centre for Psychedelic Science (TCPS)
Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).
“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.
“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.
Journey’s Product Monetization & Market Potential for Nutraceutical Supplements
Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.
Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.
In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.
With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.
Amalgamation Agreement and Financing
Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.
In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.
To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.
Cybin Inc. (NEO: CYBN) (OTC: CLXPF), closed Wednesday’s trading session at $1.70, off by 4.4944%, on 273,946 volume with 545 trades. The average volume for the last 3 months is 335,480 and the stock's 52-week low/high is $0.0284/$2.23499989.
- Advocates Worried by Insufficiency of Information on Psychedelic Treatments in Nova Scotia
- Could Psychedelic Medicines Soon Be Widely Available in the UK?
- Local Legislators in Massachusetts Unanimously Vote to Decriminalize Psychedelics
Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF)
Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) was highlighted today in a publication from Investorideas.com, examining a sector snapshot featuring comments and insights from leaders in Hydrogen Tech discussing the future of a Hydrogen economy. The Canadian government released its Hydrogen strategy for a global hydrogen market that will be worth $12 trillion by 2050 stating, "Hydrogen might be nature's smallest molecule but its potential is enormous. It provides new markets for our conventional energy resources, and holds the potential to decarbonize many sectors of our economy, including resource extraction, freight, transportation, power generation, manufacturing, and the production of steel and cement."
Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) is an investment holding company that focuses on investing in and providing early-stage financing to both public and private businesses. Since its original listing with the Canadian Stock Exchange (“CSE”) on January 23, 2019, the company has made investments in a number of different businesses in a variety of industries, including the energy and cannabis sectors. As per the company’s investment policy, its primary goal is to identify and capitalize on high-return investment opportunities presenting the ability to achieve capital appreciation and liquidity.
Clean Power Capital continues to be opportunistic in evaluating prospects across the renewable energy, bio-medical, pharmaceutical and naturopathic sectors, both as an investor and as an operator. The company’s main focus at the moment is to identify such opportunities in the renewable energy industry, including wind, solar and geothermal power and hydrogen and fuel cell technologies, as well as in the biomedical, pharmaceutical and naturopathic sectors, which may include medical or recreational cannabis.
Clean Power Capital currently has 10 investments in a variety of sectors and successfully held nearly C$120 million in investments during the past fiscal year (https://ibn.fm/8oktZ). It returned capital to its shareholders through the distribution of its interest in AgraFlora Organics International Inc. in May 2020 (https://ibn.fm/FRAvq).
Headquartered in Vancouver, British Columbia, Clean Power Capital was formerly named Organic Flower Investments Group Inc. As of November 10, 2020, the company officially changed its name to Clean Power Capital and started trading on the CSE under new ticker symbol ‘MOVE’.
PowerTap Acquisition, Hydrogen Fueling Infrastructure Collaboration
In alignment with its updated investment policy, a reconstituted investment committee and a revised strategy to reflect its focus on the renewable energy market, Clean Power Capital recently completed the acquisition of a 90 percent equity interest in California-based PowerTap Hydrogen Fueling Corp.
Leveraging an impressive portfolio of IP and advanced deployed technologies developed over two decades via substantial investments and partnerships, PowerTap is working on building and expanding a hydrogen filling station network, initially across North America. The company believes that its platform has a significant advantage over other hydrogen fueling stations, because it has a smaller physical footprint and further has the capacity to produce hydrogen fuel on site. As most other hydrogen fueling stations buy hydrogen for storage at higher costs, PowerTap’s model is believed to be exponentially more cost-effective and expandable.
Clean Power Capital’s investment and acquisition will allow PowerTap to step up its efforts and begin work on the hydrogen fueling station network in stages, starting with engineering and design, ongoing development of PowerTap’s third generation product and, finally, licensing & permitting and site preparation. Development is expected to begin in Q4 2021 with engineering and design. Overall, the initial portion of the project is expected to cost $17 million, with Clean Power Capital and PowerTap planning to secure government financing and credit, as well as equity, debt and convertible debt offerings, to fund the infrastructure’s development.
PowerTap technology is already deployed across multiple hydrogen fueling stations in public and private enterprises spanning California, Maryland, Massachusetts and Texas. The company plans to deploy its hydrogen fueling infrastructure at existing truck stops and gas stations across the country, beginning with up to 1,000 stations within the next three to five years. At the moment, there are roughly 70 active hydrogen fueling stations operational and available to consumers in the United States.
Hydrogen Industry Outlook
The project is expected to bring significant opportunities for PowerTap and Clean Power Capital on the fast-growing hydrogen market, driven by a worldwide focus on clean energies and environmentally friendly fueling solutions for the transportation industry.
Hydrogen-powered vehicles come with tremendous advantages over gas, diesel and even electric vehicles in terms of cost per mile, fueling time and driving range, as well as boasting significantly lower emissions. Well-established vehicle manufacturers such as Hyundai, Toyota, Daimler and Volvo are already including hydrogen-powered cars in their product lineups, and Nikola Motors has announced plans to manufacture hydrogen electric long-haul vehicles.
“As an experienced developer of technology in an important area that is finally having its time as a green but also economically compelling energy option, PowerTap is intent on becoming a leading part of the multi-billion dollar hydrogen fueling space,” PowerTap CEO Raghu Kilambi explained in a news release on October 28, 2020 (https://ibn.fm/oaXem).
A recent industry report developed by a coalition of major oil and gas, power, automotive, fuel cell and hydrogen companies indicates that the sector is expected to grow to $140 billion a year in revenue by 2030, creating 700,000 jobs in the U.S. alone (https://ibn.fm/UMI5q). According to Fuel Cell and Hydrogen Energy Association President Morry Markowitz, the sector could expand to $750 billion a year in revenue and 3.4 million jobs by 2050.
The U.S. is already engaged in the hydrogen economy, having more than half of the global number of fuel cell vehicles and investing hundreds of millions of dollars a year, but the country can greatly expand its global energy leadership by scaling up operations in the hydrogen economy, per the industry report.
With the upcoming change in administration in January 2021, the U.S. is expected to renew its commitment to clean energy. Moreover, the U.S. federal government is expected to invest significantly in clean energy and related infrastructure, including hydrogen, according to PowerTap.
“As the U.S. federal government has previously invested in the PowerTap technology, we are optimistic that we will have a seat at the table when USA clean energy/hydrogen infrastructure spending initiatives are designed,” Kilambi added.
Joel Dumaresq is the CEO and interim CFO of Clean Power Capital. He is a proven executive with extensive operational and senior management experience in mining, energy and alternative energy, as well as the cannabis and hemp space. Dumaresq began his career in the corporate finance space, having spent 12 years with RBC Dominion Securities. He brings 30 years of experience in the financial sector to the company, has been instrumental in raising over $250 million in venture capital finance, and he has personally managed a number of successful public listings.
Brendan Purdy serves as a director of Clean Power Capital. An experienced businessperson who has led five different companies, Purdy brings years of experience in different industries, including cannabis, blockchain and data security, gaming, mining and energy, and finance and law. He received a graduate degree from the University of Ottawa and an undergraduate degree from the University of Western Ontario.
Theo van der Linde serves as a director of Clean Power Capital. He is a Chartered Accountant with over 20 years extensive experience in finance, reporting, regulatory requirements, public company administration, equity markets and financing of publicly traded companies. He has served as a CFO & Director for a number of TSX Venture Exchange- and Canadian Securities Exchange-listed companies over the past several years. His industry experience spans the financial services, manufacturing, oil & gas, mining and retail industries. More recently, van der Linde has been involved with future use trends of natural resources, as well as other disruptive technologies.
Raghu Kilambi is the CEO and CFO of PowerTap Hydrogen. He is a seasoned investor and entrepreneur with over 25 years of global business experience in public and private investments, building businesses and creating shareholder value. He has raised over $1 billion of equity and debt capital for private and public companies and been involved in many M&A acquisitions and exits.
Clean Power Capital Corp. (OTC: MOTNF), closed Wednesday’s trading session at $2.168, off by 7.8114%, on 227,909 volume with 406 trades. The average volume for the last 3 months is 248,833 and the stock's 52-week low/high is $0.0315/$2.78999996.
- Hydrogen stocks Snapshot - Leaders in Hydrogen Tech Talk about the Future Hydrogen Economy
- GreenCarNewsBreaks - Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) Investee Company Executes Definitive Agreement with Andretti Group
- Clean Power Capital Corp. (CSE: MOVE) (OTC: MOTNF) (FWB: 2K6A) Welcomes California Planned $1.5B Stimulus for Hydrogen Fueling Infrastructure
Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF)
Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers collaborates with Canopy Growth to identify strategic counterparties seeking financial and/or operating support. Headquartered in Toronto, Canada, Canopy Rivers has developed an ecosystem of complementary cannabis operating companies operating throughout the cannabis value chain.
Canopy Rivers, in collaboration with Canopy Growth, has established a diverse portfolio of cannabis industry investments that includes domestic and international companies, licensed producers, late-stage licensed producer applicants, pharmaceutical formulators, brand developers and distributors, retail networks, and technology and media platforms. Investments are customized for each counterparty and include a balanced mix of equity, debt, royalty and profit-sharing agreements.
Canopy Rivers’ expanding portfolio includes:
- Agripharm Corp. (private) is an ACMPR licensed producer, acquired by Canopy Growth in January 2017. In November 2017 Agripharm completed a joint venture with globally recognized partners Green House Seeds and Organa Brands. Canopy Growth has sublicensed proprietary technology, trademarks, genetics, know-how and other intellectual property from Agripharm to distribute the suite of Green House and Organa Brands products across the country, when permissible.
- CanapaR Corp. (private) owns 80% of CanapaR Italy, a Sicily-based company focused on developing and commercializing Italy’s local hemp cultivation industry through its partnership with the renowned Department of Agriculture at the University of Catania and its rapidly building extraction capabilities for the production of organic CBD oil. CanapaR Italy’s outsource farming model with local Sicilian farmers and its university partnership will provide it with a low-cost source of organic CBD oil, which is increasingly used as an input into new commercial products in the growing health and wellness industries.
- Civilized Worldwide Inc. (private), is a media and lifestyle brand with offices in New Brunswick and California that embraces and highlights modern cannabis culture. Civilized aims to engage the millions of productive, motivated people who choose to enjoy cannabis responsibly as part of their lifestyle. Reaching 2+ million unique visitors per month, North America-wide, Civilized produces engaging content for and about people who enjoy cannabis responsibly.
- James E. Wagner Cultivation Ltd. (TSXV:JWCA) was founded in 2007 by third generation agricultural and cannabis cultivators. JWC is the first entirely aeroponic producer of cannabis in Canada, and its patent-pending aeroponic production technology, called GrowthStormTM, allows for perpetual harvesting and improved yields. The company was issued a license to cultivate from Health Canada in January 2017 and a subsequent sales license in March 2018.
- LiveWell Foods Canada Inc. (TSXV:LVWL) was established in 1993 as a nutritional lifestyle company, and operates in the production of fresh produce and food technology. The company’s O-Hemp division distributes bulk and retail hemp products through its existing channel partners. LiveWell entered into a strategic agreement with Canopy Rivers and Canopy Growth in April 2018.
- PharmHouse (private) is a joint venture between Canopy Rivers and the principals and operators of leading North American greenhouse produce companies. PharmHouse has arranged to acquire a newly built 1.3-million-square-foot greenhouse located in Leamington, Ontario.
- Radicle Cannabis Inc. (private) is an ACMPR-licensed cannabis company based in Hamilton, Ontario backed by a management team that brings extensive experience in regulated industries, retail distribution, tobacco and pharmaceutical development, as well as Award-winning cannabis horticulturist breeders and medical professionals.
- Solo Growth (TSXV:ALZ) is a new cannabis retail concept that will operate locations under the name “YSS by Solo,” relying on the expertise of a management team comprised of founding shareholders, senior officers and board members of Solo Liquor Stores Ltd., a leading Canadian liquor retailer. Solo Growth was established through a recapitalization of Aldershot Resources Ltd.’s corporate structure that will allow the company to execute a new retail-focused cannabis business strategy.
- Spot Therapeutics Inc. (private) is an applicant that was acquired by Canopy Growth in August 2017 to solidify its Maritimes expansion strategy and less than four weeks later Canopy Growth signed a supply MOU with the New Brunswick government. Canopy Rivers purchased the property and entered into a long-term lease and committed funding agreement with Canopy Growth.
- TerrAscend Corp. (CSE:TER) cultivates high-quality cannabis in an indoor hydroponic facility, backed by a strategic investor boasting a strong background in the pharmaceutical space and an extensive portfolio of specialty pharma assets.
- Vert Mirabel (private) is a joint venture that was established in December 2017 between Canopy Rivers, Canopy Growth, and Les Serres Stephane Bertrand. Bertrand is a large-scale greenhouse operator located in Mirabel, Quebec, and the largest grower of pink tomatoes in the country. With guidance and assistance from Canopy Growth, the greenhouse has been upgraded and retrofitted for cannabis production and was licensed by Health Canada in May 2018.
As the company’s portfolio continues to develop, each constituent benefits from opportunities to collaborate with Canopy Growth and among themselves. Canopy Rivers believes this formula results in an ideal environment for innovation, synergy and value creation for Canopy Rivers, Canopy Growth and across the entire Rivers ecosystem.
Canopy Rivers is led by an experienced team of qualified financial and technical professionals with deep industry experience and relationship networks. The company’s acting CEO and chairman is Bruce Linton, CEO of Canopy Growth and founder of Tweed Marijuana.
Canopy Rivers Inc. (CNPOF), closed Wednesday’s trading session at $1.50, off by 4.4586%, on 318,386 volume with 348 trades. The average volume for the last 3 months is 482,860 and the stock's 52-week low/high is $0.371499985/$1.64999997.
- CannabisNewsBreaks - Canopy Rivers Inc. (TSX: RIV) (OTC: CNPOF) to Release Q3 Financial Results, Host Conference Call on February 10
- Cannabis Isolates Cross Over to Pharmaceutical-Grade Products Are More Prevalent Than Ever
- Cannabis Delivery Services Are Becoming One of the Hottest Revenue Streams in Cannabis Market
CNS Pharmaceuticals Inc. (NASDAQ: CNSP)
Biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP) recently took part in the H.C. Wainwright Bioconnect 2021 Virtual Conference, which took place January 11-14, 2021. CNS’s CEO John Climaco gave a presentation at the event, discussing how the clinical-stage biopharmaceutical company is developing novel treatments for primary and metastatic cancers of the brain and central nervous system (https://ibn.fm/7zYST).
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.
The company was founded in 2017 and is headquartered in Houston, Texas.
Organ Targeted Therapeutics
The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.
CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.
CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.
CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.
CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.
The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.
CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.
Global Brain Tumor Therapeutics Market
The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.
A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.
Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.
Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.
One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).
John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.
Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.
Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.
Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.
CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Wednesday’s trading session at $1.87, off by 12.2066%, on 2,248,539 volume. The average volume for the last 3 months is 1,460,648 and the stock's 52-week low/high is $1.25820004/$5.61999988.
- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Discusses Product Pipeline, Clinical Trial Plans, at H.C. Wainwright Bioconnect 2021 Virtual Conference
- Tired of Dairy? Tel Aviv Researchers May Have Just What You Need, Milk From Yeast!
- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Moving Forward with New Berubicin Clinical Trials, Determined to Help Address Unmet Needs of GBM Patients
Predictive Oncology (NASDAQ: POAI)
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has closed of its previously announced registered direct offering. The offering comprised 3,414,970 shares of POAI’s common stock, offered at a purchase price of $1.20 per share, which was priced at-the-market under Nasdaq rules. The announcement noted that gross proceeds from this offering for Predictive Oncology will total approximately $4.1 million, before fees and other offering expenses are deducted. To view the full press release, visit: https://ibn.fm/I5CFV
Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.
Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:
- A database of clinically validated historical and outcome data from patient tumors
- An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
- A “smart” patient-derived tumor profiling platform
- An in-house bioinformatics artificial intelligence (AI) platform
- A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
- An FDA-approved fluid collection and disposal system
Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.
Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.
Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.
In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.
TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.
Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.
The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.
Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.
Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.
Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.
Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.
CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.
Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.
Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.
Predictive Oncology (POAI), closed Wednesday’s trading session at $1.17, off by 12.0301%, on 4,348,861 volume. The average volume for the last 3 months is 1,952,564 and the stock's 52-week low/high is $0.629999995/$5.30000019.
- BioMedNewsBreaks - Predictive Oncology (NASDAQ: POAI) Closes Registered Direct Offering for $4.1 Million
- Predictive Oncology Announces Closing of $4.1 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
- BioMedNewsBreaks - Predictive Oncology (NASDAQ: POAI) Closes Registered Direct Offering for $2.2 Million, Announces $4.1 Million Registered Direct Offering
Green Hygienics Holdings Inc. (OTCQB: GRYN)
As an innovative technology-driven enterprise, Green Hygienics Holdings (OTCQB: GRYN) is dedicated to delivering the highest operating standards of industrial hemp cultivation and processing, and manufacturing of pharmaceutical-grade bioactive cannabinoids. Poised to bring safe and consistent products to market and thus change the industry’s landscape and enhance consumer confidence, GRYN is committed to becoming the most highly certified hemp company in the industry (https://cnw.fm/nOulJ). Also today, the company was featured in the 420 with CNW by CannabisNewsWire.
Green Hygienics Holdings Inc. (OTCQB: GRYN) is a California-based innovative technology-driven enterprise focused on the high standard cultivation and processing of industrial hemp and manufacturing of pharmaceutical-grade bioactive cannabinoids.
The company aims to be a leader in compliance and capabilities in the hemp and cannabinoid supply marketplace. By leveraging state of the art technologies, the company intends to open up a whole new world of novel cannabinoids and targeted bio-delivery technologies never before explored, solving the issues of stability, pharmacokinetics, biological tissue penetration and bioavailability.
Dedicated to creating the hemp industry’s safest and finest quality products, the company will be uniquely positioned to deliver product efficacy and supply chain solutions to consumers, as well as to leverage these within its own products and brand portfolio.
USDA Organic Certification and FDA Registration
On August 26, 2020, Green Hygienics registered with the U.S. Food and Drug Administration pursuant to the Federal Food Drug and Cosmetic Act, as amended by the Bioterrorism Act of 2002. This registration strengthens the company’s core mission to provide product efficacy to the pharmaceutical industry and consumers alike.
On September 30, 2020, Green Hygienics was granted USDA Organic Certification (7 CFR Part 205) for the cultivation and post-harvest processing of industrial hemp by the California Certified Organic Farmers for its Sol Valley Ranch property. This certification further enables the company to supply certified organic hemp products to national and international markets.
Green Hygienics is focused on finding, acquiring and developing strategically positioned businesses, as well as the best innovations within the hemp industry – a fast-progressing market with remarkable opportunities for growth. The industrial hemp market is expected to reach $5.33 billion in 2020 and is projected to rise to $15.26 billion by 2027, achieving a CAGR of 15.8%, per Grand View Research.
GRYN has less than 42 million shares outstanding, fully diluted. The company has just 7.2 million common shares in float and boasts a balance sheet with no toxic debt or overhang.
Dr. Levan Darjania serves as the company’s Chief Science Officer. Darjania has over 26 years of experience in biotechnology and pharmaceutical drug development. His research and development experience has led him to develop many in-house and collaborative R&D programs over the course of his career.
Kyle MacKinnon serves as GRYN’s Chief Operating Officer. He has extensive knowledge in cannabis processing and was previously the Business Development Manager of Advanced Extraction Systems Inc., a leader in CO2 Supercritical Fluid Extraction. MacKinnon brings over 20 years of sales and management experience to the company.
Ronald Loudoun is the President, CEO, Secretary and Director of Green Hygienics. He received an undergraduate business degree from the British Columbia Institute of Technology. Before joining Green Hygienics, he was the founder and a director of renewable energy firm Archer CleanTech Inc.
Jerry Halamuda is the Senior Vice President of Business Development of the company’s Agriculture Division. He has an extensive career working in the agriculture and horticulture industry. Halamuda has founded, managed and operated multiple successful companies, including Color Spot Nurseries.
John Gildea is GRYN’s Senior Vice President of Corporate Development. He has over 20 years of experience working within the private and public markets. His expertise includes negotiating and structuring private and public financing and mergers. During the course of his work, Gildea has established trusted relationships with a network of equity and capital partners.
Green Hygienics Holdings Inc. (OTCQB: GRYN), closed Wednesday’s trading session at $0.82, off by 1.2048%, on 19,032 volume with 29 trades. The average volume for the last 3 months is 21,109 and the stock's 52-week low/high is $0.300000011/$2.00.
- Green Hygienics Holdings (GRYN) Leverages FDA Registration, USDA/CCOF Certification as Powerful Competitive Differentiator
- 420 with CNW - Trump Releases a Dozen Marijuana-Related Convicts Using Presidential Clemency Powers
- Green Hygienics Holdings Inc. (GRYN) Announces Partnership with Leading Hemp Law Firm
GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF)
GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF) (FSE: 4QS), a Canada-based company engaged in the business of acquiring and exploring mineral resource properties, has hired Drillex Chile SpA for its upcoming phase 1 drill program. Drillex has more than four decades of experience in exploration and resource-definition drilling and is led by an impressive executive team. The addition of Drillex to GoldHavens’ world-class geological team marks GOH’s commitment to its drilling program. To view the full press release, visit https://ibn.fm/iRYMw
GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF) (formerly Altum Resources Corp.), a Canada-based company engaged in the business of acquiring and exploring mineral resource properties, recently announced its entry into agreements to acquire seven advanced gold projects in the Maricunga Gold Belt of Chile that hosts over 100 million ounces of gold within the last 10 years.
Chilean Gold Properties Being Acquired
On April 17, 2020, GoldHaven Resources entered into an agreement to purchase a 100% interest in two gold projects located in the Maricunga Gold Belt of Northern Chile. The first property, Rio Loa, is located 25 kilometers south of Gold Fields Ltd.’s Salares Norte, where, this year, a five-million-ounce discovery was made. The second property, Coya, is located only 10 kilometers east of the Kinross La Coipa open pit mine, which has produced over 7.5 million ounces of gold to date.
Rio Loa Project
Initial geophysical studies of the Rio Loa site have exposed highly anomalous ardennite and lead values, a key characteristic of gold mineralization within silicified resistive bodies. The studies have also produced initial findings which are similar to those seen at contiguous mines, such as Salares Norte (operated by Gold Fields), which has over five million ounces in estimated gold deposits.
The potential economics for the site look particularly promising when taking the unit costs at the neighboring Salares Norte mine into account. Gold Fields has estimated that its production AISC (all-in sustainable costs) will approximate $552 per ounce and have forecast a 2.3-year payback period for its initial investment, assuming a $1,300 per ounce gold price.
The Coya site is located within close proximity to one of the richest and largest epithermal gold and silver districts in Chile and is in close proximity to active mining sites, specifically the La Coipa mine owned by Kinross. A study carried out in 2017-2018 on the Coya site of 796 rock chip samples found favorable gold and silver values, in some cases ranking as high as 764 grams/tonne of gold and 719 grams/tonne of silver – values which are near certain indicators of potential gold and silver deposits. The La Coipa mine (Kinross) has produced over 6.9 million ounces of gold to date.
On August 11, 2020, GoldHaven Resources acquired five potential gold projects in the Maricunga Gold Belt of Northern Chile. The Maricunga hosts discoveries within the last 10 years of over 100 million ounces of gold and over 450 million ounces of silver. These newly acquired properties are in close proximity to seven other mines, which possess an estimated aggregate of 81 million ounces of gold in total reserves.
GoldHaven’s five new projects cover a total area of approximately 22,600 hectares, or 226 square kilometers, located in the northern portion of the Maricunga Belt in proximity to the 5 million-ounce gold equivalent Salares Norte project owned by Gold Fields. Gold Fields announced in April 2020 its intention to proceed with the development of Salares Norte at a cost of $860 million, with a $138 million expenditure budgeted for 2020.
The Maricunga Belt extends approximately 150 kilometers north-south and 30 kilometers east-west, straddling the border between Chile and Argentina. This region hosts known mineral resources of more than 100 million ounces of gold, 450 million ounces of silver and 1.3 billion pounds of copper.
The Maricunga project’s opportunity came about as a result of a $150 million initiative launched by the Chilean Economic Development Agency (“CORFO”), with the objective of encouraging exploration and mining prosperity in Chile and strengthening Chile’s position as a world leader in the sector.
As part of CORFO’s program, a total of $15.3 million was given to private equity fund IMT Exploration to evaluate 403 projects, beginning in 2011. This led to a generative program carried out from 2016 to 2019, resulting in 126 potential epithermal targets from which 57 field evaluations were made. Due diligence work followed on 19 of these. Work programs were then conducted, including geological mapping, rock and soil sampling and TerraSpec (PIMA) analyses on geochemical grids for alteration mapping, and, as a result, the five high-priority Maricunga projects were identified. No drilling has been carried out on any of the Maricunga projects.
Securing Financing for Upcoming Operations
In conjunction with its announcement regarding its acquisition of five Chilean mining interests, GoldHaven Resources also detailed plans for a non-brokered private placement of 11.5 million units at a price of $0.35 per unit, for gross proceeds of $4,025,000. Each unit will consist of one share of the company and one warrant, the latter of which can be exercised to acquire an additional share of the company for a period of 18 months from the date of issuance at a price of $0.50 per share. Net proceeds from the offering are intended to be used to fund general expenses, as well as exploration and drilling of its mineral properties.
Gold Prices Hit Record High in 2020
Gold prices have been on a remarkable run in 2020, breaking above $2,000 per ounce for the first time on record. Having begun the year at $1,515 per ounce, the precious metal has seen a huge surge on the back of widespread economic uncertainty stemming from governments’ worldwide propensity to expand the money supply, from the reduction of the value of the U.S. dollar as expressed by the decrease in the U.S. dollar index, and from the very real economic effects of the COVID-19 pandemic.
Global central banks have carried out 144 interest rate cuts thus far in 2020, reducing rates by a cumulative 5,035 basis points (http://nnw.fm/jzZt0). Meanwhile, the IMF has estimated that global governments have introduced fiscal support measures amounting to over $9 trillion since the start of the pandemic (http://nnw.fm/Or9rI). The resulting weakness in the U.S. dollar and eventual inflationary pressures stemming from these measures has prompted a number of investment banks to boost their near-term outlooks for gold prices, with Bank of America raising its 18-month gold price target to $3,000 per ounce (http://nnw.fm/PQJtc).
David Smith, President, CEO and Director, has been immersed in the mining industry for the last eight years, working in corporate development and finance. Prior to GoldHaven Resources, Smith cofounded a multifaceted real estate development and sales company, which has now been in operation for over 35 years. He also cofounded two successful environment-focused companies listed on the Toronto Stock Exchange. Both companies were sold independently and returned a significant profit for shareholders.
Darryl Jones, Chief Financial Officer, is a finance executive and CPA with over 30 years of public company and project buildout experience. Most recently, Jones served as the CFO of Lupaka Gold Corp., retiring in June 2018. Prior to that, Jones serves as CFO of Corriente Resources, which was sold to CRCC-Tongguan in May 2010 for C$680 million.
Patrick Burns, VP Exploration and Director, is a Canadian geologist with over 40 years of experience throughout the Caribbean and Central and South America. He played a direct role in the discovery of the Escondida porphyry copper deposit in Chile and has been involved in publicly traded mining companies, predominantly in Chile, for 35 years.
Marla Ritchie, Corporate Secretary, brings over 25 years of experience in public markets to the GoldHaven team. Throughout this time, she has worked as an administrator and corporate secretary specializing in resource-based exploration companies. Currently, Ritchie is the corporate secretary for several companies, including International Tower Hill Mines Ltd. and Trevali Mining Corp.
Gordon Ellis, Director; has over 50 years’ experience in mining and resource development. A professional engineer and entrepreneur, he has held multiple senior management and director roles with public mining companies, as well as a multi-billion-dollar ETF fund. Ellis holds an MBA in international finance and a Chartered Directors designation.
Scott Dunbar, Director is a professor and head of multiple departments at the University of British Columbia, including mineral extraction and mining innovation, as well as mining engineering. He has been involved in projects around the world in regard to mining exploration, geotechnical engineering and mine design. Dunbar received his PhD in geophysics and civil engineering from Stanford University.
GoldHaven Resources Corp. (OTCQB: GHVNF), closed Wednesday’s trading session at $0.70504, off by 4.0762%, on 91,226 volume with 56 trades. The average volume for the last 3 months is 106,241 and the stock's 52-week low/high is $0.109999999/$0.83069998.
- MiningNewsBreaks - GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF) (FSE: 4QS) Announces Conference Attendance, Hiring of Drillex Chile SpA for Drill Program
- GoldHaven Hires Drillex Chile SpA for the Phase I Drill Program and Outlines Upcoming Conference Attendance
- GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF) Grows Stronger, More Stable in Uncertain Year
Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF)
Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF), a plant-based extraction company specializing in cannabis, hemp and mushroom products, this morning announced that its common shares on the OTC Market under the symbol "PRXTF" are now eligible for electronic clearing and settlement through The Depository Trust Company ("DTC"). “DTC eligibility is a major step forward in increasing liquidity, broadening our shareholder base and building a strong presence for our company within the US capital markets sphere. This is an important step in amplifying our story to a wider audience,” Pure Extracts CEO Ben Nikolaevsky stated in the news release. To view the full press release, visit https://ibn.fm/A82TS. Also today, the company was featured in the 420 with CNW by CannabisNewsWire. A significant amount of research has been done on the different ways that various cannabinoid formulations can affect an individual’s driving skills, telephone or computer skills, memory or even work productivity.
Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF), headquartered in Pemberton, British Columbia, is a plant-based extraction company with a new vertical in functional mushrooms. The firm is positioned to be the dominant extraction company and a leader in the rapid development and commercialization of functional and medicinal psychedelic products.
The Company’s business model consists of three verticals: in-house brands; toll processing, offering contract cannabis and hemp processing to Canadian Licensed Producers and international partners to sell under their own brands; and white labelling, supplying products, including edibles and custom formulated oils, in consumer-ready packaging for companies licensed to sell cannabis oil extracts and for CPG brands seeking licensed cannabis manufacturing partners.
The psychedelic and functional mushroom industries are among the fastest growing in North America. As the industry transitions from dry biomass to extracts, many companies are unprepared for this new opportunity. The global medicinal mushroom market is expected to grow by $13.88 billion annually by 2024.
When assessing investment strategy, market analysts suggest that psychedelics are more comparable to biotech than to cannabis. Unlike traditional biotech, however, psychedelics can claim years of human consumption. Because their efficacy and safety are already well understood, the hurdles for development are likely to be lower. As known molecules, psychedelics won’t spend as much time in discovery and pre-clinical development.
Current research is finding psychedelic benefits including anti-tumor, anti-viral, detoxification, immune function, and mental wellness. As such, psychedelic compounds are now being examined by leading medical research and academic institutions for treatment of depression, PTSD, anxiety, bi-polar disorder, obesity, narcolepsy, OCD, Alzheimer’s, ADHD and drug and alcohol dependence. In 2020, the FDA granted breakthrough therapy status to psychedelics for treatment-resistant depression, with approvals anticipated in 2021.
Pure Extracts is well positioned to partner with organizations planning to develop both functional and psychedelic products. A dealer’s license with Health Canada will enable buying, selling and producing of psychedelics in an EU-GMP-compliant environment. The Company’s 10,000 square foot facility is designed for EU-GMP certification, which allows for international sales. The Company has signed NDAs to explore joint development endeavors for Q4 2020 product launches, as well as an advisory agreement with Dr. Alexander MacGregor, founder of Transpharm Canada Inc. (“TCI”), the parent company of Toronto Institute of Pharmaceutical Technology, whose facility is a fully compliant Health Canada licensed Good Manufacturing Practice (“GMP”) manufacturing and testing facility and is a full-service clinical development business that provides clinical trial services to biotechnology companies.
Research on Psychedelics
Naturally occurring psychedelics, like psilocybin mushrooms, peyote and ayahuasca, have been used by humans for centuries. First seen as potentially medicinal in 1938 by a chemist at Sandoz Pharmaceuticals (now Novartis), the desired stimulant effect was unsuccessful and therefore the drug was shelved. Twenty years later, in 1958, Sandoz began selling lysergic acid diethylamide (LSD) to treat mental disorders. From 1950 to 1965, over a thousand scientific papers on these compounds were published. During the 1960s, however, psychedelics made their way out of the lab and onto the street. The war on drugs followed, and psychedelic research essentially ended.
Research continued slowly on the fringes. The Multidisciplinary Association for Psychedelic Studies was formed in 1986 with the goal of becoming a leading non-profit psychedelic pharmaceutical company. Still being researched, psychedelics’ primary and most common mechanism of action is agonism of serotonin receptors in the brain, which promotes serotonin production in order to regulate mood.
Growing societal awareness and acceptance of mental illness as a legitimate disease due, in part, to its increasingly prevalence have been a catalyst for a new search for innovative treatments. As such, interest in psychedelic medicines has been revived in recent years.
Extract Segment Leader with Cannabis
Canada’s cannabis industry is dominated by dried flower products. Extract products are estimated to represent only 13% of the market share. With no dominant brands in the cannabis sector, Pure Extracts is the development leader in this segment, which is estimated by Deloitte to be worth $2.7 billion annually. Pure Pulls, the company’s private label brand, is nationally recognized through compliant event sponsorship and ongoing product engagement.
Pure Extracts is led by a team of dedicated professionals leveraging extensive industry knowledge.
Ben Nikolaevsky, the company’s CEO, has more than a decade of experience in corporate leadership roles across the natural products, agriculture and cannabis sectors. Nikolaevsky has served as CEO at Natura Naturals Inc. and Blue Goose Capital Corp., as well as market vice president at CIBC and chief credit officer & capital markets manager at IBM Global Financing Canada.
Doug Benville founded Pure Extracts and serves as the company’s COO. He is highly proficient in cannabis cultivation, system operations and oil extraction.
Alexander Logie, Pure Extracts’ vice president of business development, has over 30 years of experience in the financial services sector, having most recently served as interim CFO, COO and senior vice president of business development at Natura Naturals Inc., a licensed cannabis producer acquired at the start of 2019.
Andy Gauvin is vice president of sales for Pure Extracts. Gauvin is an accomplished senior sales leader with over 30 years of experience in the cannabis space. Gauvin also brings extensive knowledge of the complex federal and provincial regulatory environment to the Pure Extracts team.
Pure Extracts Technologies Corp. (CSE: PULL), closed Wednesday’s trading session at $0.527, off by 3.7443%, on 125,068 volume with 75 trades. The average volume for the last 3 months is 53,050 and the stock's 52-week low/high is $0.455659985/$1.00.
- PsychedelicNewsBreaks - Pure Extracts Technologies Corp.'s (CSE: PULL) (OTC: PRXTF) US Shares Gain DTC Eligibility
- 420 with CNW - How Will CBD Impact Your Work Performance?
- Mount Sinai Opens Psychedelics Research Center
Josemaria Resources Inc. (TSX: JOSE) (OTC: JOSMF)
Josemaria Resources Corp. (TSX: JOSE) (OTCQB: JOSMF) was featured today in a publication from MiningNewsWire, examining how a recent report released by Fact MR on the mining pumps market provides extensive coverage of key factors and market growth that are driving the sustained growth of the market landscape around the world. The report states that a significant increase in mining activities globally, pushed by proactive investments, may cause a constant rise in the demand for mining pumps. By the end 2018, the sales of mining pumps had probably exceed more than 3.5 million units.
Josemaria Resources Inc. (TSX: JOSE) (OTC: JOSMF) is a Canadian natural resources company based in Vancouver, British Columbia. The company’s current focus is on advancing the development of its wholly owned Josemaria copper-gold mining project.
Josemaria Resources is part of The Lundin Group of companies, a conglomerate of 13 business entities operating in the mining, oil and gas and renewables sectors all around the world.
The Josemaria Copper-Gold Project
The company’s flagship Josemaria Copper-Gold Project is located in the San Juan Province of Argentina – a well-known mining hub supporting a wide variety of mining service companies. The Lundin Group has been active in Argentina for approximately 30 years. Committed to advancing the project, Josemaria Resources has already begun the bridging phase, with basic and detailed engineering planning expected to commence in early 2021.
The company recently announced the results of a feasibility study at the Josemaria Project. The study, prepared by a team of engineering and consulting providers including Fluor Canada Ltd., SRK Consulting (Canada) Inc. and Knight Piésold Ltd., highlights a robust, low-risk project with rapid payback expected via an open pit operation with forecast capacity to feed a conventional process plant at a rate of 152,000 tonnes a day over a 19-year mine life.
According to the feasibility study, the project is expected to yield an average annual production of 136,000 tonnes of copper, 231,000 ounces of gold and 1,164,000 ounces of silver. Other highlights of the study include:
- The optimized mining production plan provides average grades in the first three years of production that are notably better than the life-of-mine average. This supports a forecast 3.8-year payback period from the start of production.
- The project’s total initial cost, including engineering, procurement, construction, management, on- and off-site infrastructure, contingency and pre-construction engineering work, amounts to roughly $3.09 billion.
- The location provides readily available access to essential resources, including water, grid power, transportation and logistics infrastructure within San Juan Province.
- An Environmental and Social Impact Assessment (ESIA) of the project is already underway and is expected to be submitted to relevant authority agencies for review during Q1 2021.
The Josemaria Copper-Gold Project has been designed to incorporate the latest technology. Per the feasibility study, the project will include the use of autonomous trucks and production drill fleets, with the option of incorporating green energy, indicating the company’s commitment to minimizing and mitigating the adverse effects of mining on the environment.
To this end, the company intends to leverage suitable planning, impact assessment and monitoring tools while also incorporating water and energy efficiency systems and ecosystem conservation services in the design and implementation of its operations.
Josemaria Resources President and CEO Adam Lundin welcomed the results of the study as confirming that this is one of the very few readily developable copper-gold projects in the world and forecasting an attractive economic outcome for the asset, comparable with other copper-gold projects in development.
“We believe that Josemaria is perfectly positioned to commence production by mid-decade, meeting rising copper demand from a rapidly electrifying global economy. I believe the study results will allow us to unlock various financing opportunities as we move toward construction,” Lundin said in a news release.
The global smart mining market was estimated at $6.8 billion in 2019. It is forecast to reach $20.31 billion by 2025. The significant increase is expected to be driven by technological advancements within the sector.
Global demand for copper is also growing steadily, due to the metal’s versatility and multiple uses for industrial, domestic and high-technology indications. The global copper market is expected to reach $222.1 billion by the end of 2026.
Adam Lundin is the President, CEO and Director of Josemaria Resources. He has several years of experience in managing capital markets and public companies across the natural resources sector. His background includes oil, gas, mining technology, investment advising, international finances and executive management. Lundin began his career working for several of the Lundin Group mining companies. He is currently engaged in multiple roles, as he is also the Chairman for Filo Mining Corp. and Africa Energy Corp. and a Director of NGEx Minerals Ltd. and the Lundin Foundation.
Ian Gibbs serves as CFO of Josemaria Resources. He is a Canadian Chartered Accountant and a graduate of the University of Calgary, holding a Bachelor of Commerce degree. Gibbs has held many prominent positions within the Lundin Group of companies over the last 15 years, most recently as the CFO of Africa Oil Corp.
Arndt Brettschneider is the company’s Vice President of Projects. He has over 23 years of international mining, consulting and project development experience. Before joining Josemaria Resources, he was Vice President of the mining consulting businesses of two globally recognized engineering companies. Brettschneider obtained a Bachelor of Science with Honors from the University of Queensland in Brisbane, Australia. He received his MBA from Queen’s University in Ontario, Canada.
Bob Carmichael is the company’s Vice President of Exploration. He joined Josemaria Resources from Lundin Mining Corporation’s UK office. In his UK role, he was the General Manager of Resource Exploration. Carmichael is a registered Professional Engineer in the Canadian province of British Columbia. He obtained a Bachelor of Applied Science from the University of British Columbia. His dual role includes serving as Vice President of Exploration for Filo Mining Corp. and NGEx Minerals Ltd.
Alfredo Vitaller is Josemaria Resources’ General Manager in Argentina. He has been involved in the mining industry since 1993. He graduated as a Licentiate in Geological Sciences from Buenos Aires University and has an M.Sc. from Mackay School of Mines at the University of Reno. Vitaller has worked with the Lundin Group since 1993 and was a part of the exploration teams for Filo, Helados and Josemaria.
Ashley Heppenstall, chairman of the Josemaria Resources board of directors, has over 30 years of experience in the oil and gas and resources sectors. From 2002 to 2015, Heppenstall served as the President, CEO and Finance Director of Lundin Petroleum AB, an oil and gas exploration and production company with core assets in Norway and Southeast Asia. He is credited with building Lundin Petroleum into the largest independent oil firm in the world today, leveraging a single equity raise of $50 million to guide Lundin in the design and implementation of a strategy that’s led it to a current market cap of roughly $6 billion.
Ron Hochstein has worked for the Lundin family directly as a consultant for over 20 years and is currently the President and CEO of Lundin Gold, a gold-producing business whose key asset is the Fruta del Norte gold deposit in Ecuador. Hochstein led construction efforts on the first mine in Ecuador, which went into production in 2019 and was completed on time and on budget.
Paul Conibear has been with The Lundin Group for over two decades, including serving as the CEO and Director of Lundin Mining from 2011 through 2018. Lundin Mining’s current market cap is estimated at $3.5 billion. In total, Conibear has more than 35 years of experience in progressively more responsible positions in the resource sector ranging through management of all phases of mine investment, including exploration, economic assessments, construction, operations and closure.
Josemaria Resources Inc. (TSX: JOSE) (OTC: JOSMF), closed Wednesday’s trading session at $0.5388, off by 3.7857%, on 9,253 volume with 12 trades. The average volume for the last 3 months is 15,350 and the stock's 52-week low/high is $0.465299993/$0.685000002.
- Report Provides Insights into the Market for Mining Pumps
- Josemaria Resources Inc. (TSX: JOSE) (OTC: JOSMF) Rapidly Developing New Copper-Gold Project in Argentina as Copper Demand Projected to Rise
- Price Levels of Tin Surge in London Market as 2021 Progresses
InsuraGuest Technologies, Inc. (TSX.V: ISGI) (OTC: IGSTF)
InsuraGuest Technologies, Inc. (TSXV: ISGI) (OTCQB: ISGIF) ("InsuraGuest" or the "Company"), through its wholly owned U.S. subsidiary InsuraGuest, Inc. ("ISG"), is proud to announce it has expanded its Hospitality Liability coverages to include accidental medical incidents occurring anywhere on a hotel's premises. In addition to coverage already available for incidents in a guest's own room, the expansion will now further protect hotels from claims made by guests should an accident occur anywhere else on the hotel premises; for example, at the pool, in the hotel gym or in the hotel parking lot.
InsuraGuest Technologies, Inc. (TSX.V: ISGI) (OTC: IGSTF) is a leading global SaaS (Software-as-a-Service) company leveraging its proprietary, flagship insurtech (insurance + technology) software, InsuraGuest, which is integrated with the property management systems of hotels and vacation rentals to deliver custom Hospitality Liability coverages.
InsuraGuest’s Hospitality Liability coverages are purchased by hotels and vacation rental properties, which can address claims from guests and their room occupants. The combination of the integrated software and customized insurance provides the property liability coverages the guests benefit from in the event a loss is incurred during their stay.
The Hospitality Liability policy is offered through integration of InsuraGuest’s API with the clients’ property management systems. InsuraGuest’s platform is currently capable of integrating with approximately 71 different hotel and vacation rental property management systems, giving it access to millions of rooms worldwide.
InsuraGuest continues to pursue expansion opportunities in the United States, and has plans to expand to its distribution platform and Hospitality Liability coverages to the United Kingdom and Europe regions by third quarter 2020, as well as expansion into Asia by the end of 2020.
Protection that Enhances the Guest’s Experience
InsuraGuest’s Hospitality Liability coverages add a layer of protection for the property on a primary basis, should a guest experience an accident or theft while staying at an InsuraGuest member hotel or vacation rental property.
The U.S. hotel industry generated more than $218 billion in annual revenues in 2018, an increase of $10 billion from the previous year, according to STR’s 2019 HOST Almanac. The European market is more than double the size of the U.S. market. According to Oxford Economics, there were 6.4 billion nights stayed in the world, with 2.6 billion hotel nights stayed in Asia, 2.8 billion nights stayed in Europe, and 1.1 billion stayed nights in the United States. Additionally, $100 billion was spent on vacation rentals in the United States, where there approximately 4.5 million second homes are being managed by a third-party rental company.
With distribution in Europe and the United States, InsuraGuest’s combined demographics will total 3.9 billion nights stayed, and will more than double its vacation rental opportunities.
Within this burgeoning, high-demand industry is risk of liability to guest injury. For example, gym injuries are among the top five most common hotel accidents. Without proper hedges in place, the property may be liable in a personal injury claim or lawsuit that are not the properties fault.
Though the potential for accidents, slip and falls and mishaps can be widespread, it can be covered under the InsuraGuest Hospitality Liability policy to provide guests a worry-free and enjoyable stay that potentially increases loyalty for the property.
- Targeting hotels and vacation rentals, a multi-billion-dollar industry
- Providing the first line of defense in case of accident, loss or death
- Expanding distribution reach with footing in European hotel and vacation rental markets
- Expansion into Asia by 2020
Douglas Anderson, Chairman & Chief Executive Officer
Douglas Anderson has been a businessman in the real estate industry for nearly 30 years. His business expertise includes master planning and development implementation for larger-scale resorts, business parks and commercial developments across the USA and two provinces in Canada. His business endeavors include the founding of the 7th larger private equity fund in America focusing on multifamily and senior care (ROC Fund/Bridge IPG Fund). He serves as chairman/founder of a golf and winter sports ski holding company with operations in four major east coast markets and British Columbia, Canada.
Anderson earned a Bachelor of Science in consumer studies with an emphasis in architecture as an undergraduate at the University of Utah. He subsequently earned his MBA. He also attended a three-year OPM Program a postgraduate business education at Harvard Business School in Boston. Anderson is an avid skier and outdoor enthusiast.
Logan Anderson, CFO & Director
Logan Anderson (bachelor’s degree in communications, accounting and economics) holds the designation of ACA with the Chartered Accountants of Australia and New Zealand. He began his career as an associate chartered accountant in New Zealand and then Canada. This was followed by his position as controller of a management services company which was responsible for the management of numerous private and publicly traded companies. Since 1993, Anderson has served as president of Amteck Financial Corp. (and its predecessors), a private financial consulting services company servicing both private and public companies. He is a former director of 3D Systems, Inc. (NYSE: DDD), and was formerly a founder, officer, and director of Worldbid.com. Anderson has also been involved in raising funds for numerous private and public companies in all stages of their development and has been an officer and director for numerous public and private companies over the past 40 years.
Charles James Cayias, President & Director
Charles James Cayias is also the president and owner of Charles James Cayias Insurance Inc. He is a third-generation insurance professional whose creativity and artistic vision have enabled him to establish a full-service agency combined with the personal service each client deserves. His outstanding people skills, honesty, integrity and fairness are evident by his loyal and growing clientele, the majority of which are referrals who become long-time customers and friends. Cayias began his insurance career in the early 1970s and has been licensed since 1977. He is licensed in all 50 states and specializes in niche programs. He has extensive expertise in all aspects of the insurance industry including commercial insurance, employee benefits, workers’ compensation, professional liability, risk management and bonding.
Tony Sansone, COO & VP of Finance
Tony Sansone has over 30 years of financial, operations and business development experience which includes serving as CFO in the health care, foodservice distribution, manufacturing and technology sectors, including public company experience. He has held senior finance positions in the banking, telecommunications, medical products, and food & drug retailer industries, closing over $430 million of private debt, equity and line of credit financings and over $350 million of a merger, acquisitions, real estate and state incentive transactions, including due diligence, negotiations, closing, and integration. Sansone coordinated and was the executive sponsor for four ERP implementations and multiple other best-in-class software & technology solutions. He received his MBA from the University of Utah and a Bachelor of Science in accounting from Utah State University. Sansone also currently serves as president-elect of the Utah Chapter of Financial Executives International and a past president and current member of the board of trustees for Catholic Community Services of Utah. He is the proud father of three children.
Christopher J. Panos, Vice President & Director
Christopher J. Panos is a highly competitive sales professional with over 15 years of territory manager sales experience and an award-winning record of achievements. He is exceptionally well organized with a proven work history that demonstrates self-discipline, superb communication skills, and the initiative to achieve both personal and corporate goals. Panos is successful in building relationships with a large network of industry professionals in order to grow and maintain new and existing business, exceed new sales objectives and provide in-depth product training to authorized dealers and sales personnel.
Alexander Walker III ESQ, Corporate Counsel & Director
Alexander Walker III ESQ has served as director of the company since September of 2018 and as counsel to the company since July of 2018. Walker is an attorney and has been a member of the Utah Bar Association since 1987 and a member of the Nevada State Bar since 2003. His practice has involved general business litigation, in both federal and state courts, and transactional work, including securities offerings and registration, corporate formation and periodic reporting compliance. Walker has provided legal services to emerging businesses throughout his carrier and at times has served as an officer and board member as well as legal counsel public companies. His duties as legal counsel for a public company engaged in the business of ownership and operation of coal-producing properties in the western United States included oversight of corporate-related legal matters including securities reporting, corporate compliance, federal and state mining regulation, and employment law oversight. He also has served as the chair of the Mining Committee of the Energy, Natural Resources and Environmental Law Section of the Utah State Bar, a member of the board of directors of the South East Utah Energy Producers Association, the co-chair of the board of the Western Energy Training Center, a board member of the Utah Supreme Court Committee to Review the ABA Recommendations Regarding the Office of Professional Conduct, and a board member of the University of Utah Crimson Club.
Jennifer Epperson, Vice President of Sales
Jennifer Epperson has over 20 years of B2B sales experience with exceptional success history. She has grown and developed sales territories across multiple industries. Her ability to find and develop strategic relationships has given her top-level performance throughout her career. Epperson’s passion and knowledge provide an inherent ability to connect and retain relationships for the growth of the company. Throughout her professional career, she has achieved peak performance sales results and awards year after year. She captures the vision of the company and drives it forward with enthusiasm and expertise. Her commitment to providing an exceptional customer experience has been the key to her success.
Richard Matthews, Interim Financial Controller
Richard Matthews joined the InsuraGuest team in March 2019 as the interim financial controller. Leading the Finance and Audit team, Matthews is responsible for the delivery of financial services such as accounting, treasury, reporting, budgeting and insurance management, in accordance with legislative requirements and organizational policies and strategies. He has over 30 years of experience in providing professional services across a broad range of finance areas including compliance, business process, audit, and financial reporting. He holds a degree in accounting from the University of Utah and is a licensed CPA in the state of Utah.
Roger Bloss, Corporate Consultant & Board Advisor
Roger Bloss joined InsuraGuest in August of 2019 to advise the company and its board on hotel transactions, contributing his knowledge from more than 40 years in the hospitality industry. Bloss previously served in executive positions with several major hotel franchise companies and in 1996 founded Vantage Hospitality Group hotel brands. Under his leadership, Vantage became a Top 10 global hotel company and made the Inc. 500/5000 list of Americas’ fastest-growing private companies for eight straight years. Bloss was named Lodging Magazine’s “Innovator of the Year” in 2006 and 2010, and in 2009 earned a spot on HSMAI’s “Top 25 Extraordinary Minds in Sales and Marketing.” Bloss joined Red Lion Hotels Corporation (RLHC) in September 2016 in conjunction with the acquisition of Vantage.
Jim Kilduff, Board Advisor
James “Jim” C. Kilduff has nearly 40 years of experience in the insurance and risk management sectors. He is a dynamic and energetic team leader and builder with extensive experience in the changes affecting the insurance business through Gas, alternative distribution, insurtechs and program business. His skillset includes experience as chief insurance officer with Outdoorsy Insurance Group, CEO with Harbor Hill Solutions Inc., and senior vice president and chief marketing officer with State National Insurance Companies. His career has spanned MGA creation and management, insurance company management, business development and underwriting, primary insurance and reinsurance.
Don Archibald, Board Advisor
Don Archibald brings to InsuraGuest’s advisory board 54 years of experience as an insurance agent. Archibald is the founder and former owner of Archibald Clarke and Defieux (ACD Insurance), as well as the co-founder and former equity partner of Sussex Insurance, and an agent with Sussex since 2014.
InsuraGuest Technologies, Inc. (TSX.V: ISGI), closed Wednesday’s trading session at $0.2153, off by 2.843%, on 2,500 volume with 1 trade. The stock's 52-week low/high is $0.079300001/$0.248799994.
- InsuraGuest Expands Its Insurance Coverage to Include Whole Hotel Premises
- InvestorNewsBreaks - InsuraGuest Technologies Inc. (TSX.V: ISGI) (OTCQB: ISGIF) Subsidiary's Hospitality Liability Coverage Now Available through Guesty Dashboard
- InvestorNewsBreaks - InsuraGuest Technologies Inc. (TSXV: ISGI) Poised to Further Cement Leading Position in InsureTech Market
The QualityStocks Numbers Report
The QualityStocks Sponsored News
The QualityStocks DailyNetwork Sponsors
About The QualityStocks Daily
The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.
Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.
"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.